Professor Margaret Hellard AM

Deputy Director (Programs); Adjunct Professor, Monash University, DEPM.

Background

Infectious diseases - focus of her work

For almost two decades Margaret’s work has centred around infectious diseases, preventing their transmission and identifying the impact of these infections in vulnerable populations. A researcher and clinician, her principal research interests are in the epidemiology of blood-borne viruses (BBVs) HIV, hepatitis B and hepatitis C, sexually transmitted infections, and improving the management of individuals who already have the infection.

Margaret has considerable experience in undertaking community-based research involving young people, injecting drug users (IDUs) and vulnerable populations, and experience in research in tertiary care institutes. She also has considerable experience in undertaking research that used new technologies (such as SMS, Facebook) for health promotion and prevention interventions.

Listen to Margaret on Episodes 5 and 7 of our How Science Matters podcast

Translational Research

Margaret has over $73 million in competitive research grants and tenders. She was recently awarded an $11.3 million grant from the Paul Ramsay Foundation for hepatitis C elimination. She was also awarded a prestigious NHMRC Program Grant worth over $7 million. Margaret has over 440 peer reviewed publications including in high ranking journals such as the Lancet, GUT, Hepatology and Clinical Infectious Diseases. She has won prizes for her work including the Victorian Public Health Award for Program Excellence and VicHealth Award for Outstanding Achievement in Health Promotions.

Margaret has considerable experience in translating research outcomes into health policy and practice. Examples include:

Margaret’s work over the past 15 years increasing knowledge and understanding of viral hepatitis transmission, testing and care has influenced policy in Australia and globally. This includes being one of a small group of advisors instrumental in WHO setting elimination targets for hepatitis B and hepatitis C. Margaret is leading implementation science research to ensure Australia meets these elimination targets; she had received funding worth over $14 million dollars to undertake this work including a prestigious NHMRC Program Grant and a NHMRC Partnership Grant. A key feature of this work is to increase the number of people being tested and treated for hepatitis C in community settings, in particular highly marginalised and vulnerable groups such as people who inject drugs. Margaret is also collaborating with researchers and governments including Georgia, Myanmar, Iceland, Kenya, India and the Netherlands on projects aiming to eliminate hepatitis C as a public health threat.
Margaret’s work over the past ten years examining the role of the injecting network on hepatitis C transmission has led to the funding of the Hepatitis C Treatment and Prevention (TAP) Study. This world first study is examining the feasibility of a nurse led model of care for hepatitis C treatment of people who inject drugs in a community setting using a network-based approach.
The identification of high rates of hepatitis C reinfection in people who inject drugs led to changes in HCV prevention education and helped characterise T cell function, which in turn is informing HCV vaccine development.
Margaret has been instrumental in the development of innovative sentinel surveillance systems for blood borne viruses and sexually transmitted infections and sexually transmitted infections both in Victoria and nationally. This work has led to the Federal Government funding ACCESS, a highly innovative national surveillance program that is able to monitor changes in the incidence and prevalence of these diseases and the cascades of care. ACCESS enables governments to evaluate the impact of their programs aimed at eliminating blood borne viruses and controlling sexually transmitted infections.
Margaret’s work, with others, on the feasibility of treating current people who inject drugs for their HCV has led to changes in the clinical management of this group and influenced the Victorian Government to fund and locate ten hepatitis C nurses in community based integrated clinics. Most recently this work has led to funding for randomised controlled study comparing community-based hepatitis C treatment with patients treated in a tertiary setting (The Prime Study).
Margaret’s prison research and public health advocacy played an important role in the introduction of free HBV vaccine and public health nurses into Victorian Correctional Facilities and increasing the availability of HCV treatment into Victorian prisons.
Her development of health promotion projects using new technologies (The FaceSpace and Queer as FK projects) led the Victorian Government to fund the Victorian AIDS Council to continue the Queer as FK project on the Facebook social network site.
In 2000, Margaret saved Victoria over $500 million when the results of her PhD research The Water Quality Study demonstrated that Victoria’s drinking water did not require filtration.

Most significant publications

C Seaman, C Morgan, J Howell, Y Xiao, W Spearman, M Sonderup, O Lesi, M Andersson, M Hellard, N Scott* (equal senior author) Use of the controlled-temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in low and middle-income countries: A modelling and cost-optimization study. (in press Lancet Global Health) Accepted April 2020
A Pedrana, J Howell, N Scott, S Schroeder, C Kuschel, J Lazarus, R Atun, R Baptista Leite, E t’Hoen, S Hutchinson, L Aufegger, R Peck, A Sohn, T Swan, M Thursz, O Lies, M Sharma, J Thwaites, D Wilson M Hellard. Global hepatitis C elimination: an investment framework. (In press – Lancet Gastro Hepatology) Accepted January 2020
N Scott, C Kuschell, A Pedrana, S Schroeder, J Howell, A Thompson, D Wilson*, M Hellard. A model of the economic benefits of global hepatitis C elimination: an investment case (In press – Lancet Gastro Hepatology) Accepted January 2020
Scott N, Sacks-Davis R, Wade AJ, Stoove M, Pedrana A, Doyle JS, Thompson AJ, Wilson DP, Hellard M. Australia needs to increase testing to achieve hepatitis C elimination. Med J Aust. May 2020;212(8):365-70.
A Wade, J Doyle, E Gane, C Stedman, B Draper, D Iser, S Roberts, W Kemp, D Petrie, N Scott, P Higgs, P Agius, J Roney, L Stothers, A Thompson*, M Hellard. Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs Clinical Infectious Diseases 2020;70:9:1900-1906
J Howell, H Chan, J Feld, M Hellard, A Thompson. Closing the stable door after the horse has bolted - should we be treating people with immune-tolerant chronic hepatitis B to prevent hepatocellular carcinoma? Gastroenterology Feb 20 2020
A Bowring, F Ampt, S Schwartz, M Stoové, S Luchters, S Baral, M Hellard, Pre-exposure prophylaxis for female sex workers: ensuring women’s family planning needs are not left behind J Int AIDS Soc. Feb 2020;23(2):e25442
CW Spearman, G Dusheiko , M Hellard, Mark Sonderup. The Lancet Seminar: Hepatitis C. Lancet. 2019;394(10207):1451-66
M Traeger, V Cornelisse, J Asselin, B Price, N Roth, J Willcox, BK Tee, CK Fairley, C Chang, J Armishaw, O Vujovic2 M Penn, P Cundill, G Forgan-Smith, John Gall, Claire Pickett, L Lal, Anne Mak, T Spelman, L Nguyen, D Murphy, K Ryan, C El-Hayek, M West, S Ruth, C Batrouney, J Lockwood, J Hoy, M Hellard, M Stoové, E Wright, for the PrEPX Study Team. Association of HIV Pre-exposure Prophylaxis with Incidence of Sexually Transmitted Infections among Individuals at High Risk of HIV Infection JAMA. JAMA. 2019;321(14):1380-1390. doi:10.1001/jama.2019.2947
G Cooke, I Andrieux-Meyer, T Applegate, R Atun, J Burry, H Cheinquer, G Dusheiko, J Feld, C Gore, M Griswold, S Hamid, M Hellard, J LIn Hou, J Howell, J Jia, N Kravchenko, J Lazarus, M Lemoine, O Lesi, L Maistat, B McMahon, H Razavi, T Roberts, B Simmons, M Sonderup, B Taylor, D Thomas, I Waked, J Ward, S Wiktor Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission The Lancet Gastroenterology and Hepatology 2019:4:135-184 http://dx.doi.org/10.1016/S2468-1253(18)

Appointments

2017: Deputy Director (Programs), Burnet Institute
2013: Associate Director, Burnet Institute
2012: Adjunct Professor, Monash University, DEPM.
2011: Head, Hepatitis Services, Infectious Disease Unit, Alfred Hospital, Victoria, Australia
2009: NHMRC Senior Research Fellow
2008: Honorary Senior Fellow, Nossal Institute, University of Melbourne, Victoria, Australia
2006: Honorary Associate Professor, Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia
2002-2006: Honorary Senior Lecturer, Department of Epidemiology and Preventive Medicine, Monash University, Australia
2002: Head of the Epidemiology and Social Research Unit (now Centre for Population Health) at Burnet Institute, Melbourne, Victoria, Australia
2001-2009: Infectious Diseases Physician, Royal Melbourne Hospital, Victoria, Australia
2000-2002: Senior Research Fellow, Department of Epidemiology and Preventive Medicine, Monash University, Australia
1996: Infectious Diseases Physician, Alfred Hospital, Melbourne, Australia

Positions

Red Cross Blood Bank Australia – Chair, Expert Review Panel on Injecting Drug User Donation Policy
Advisory Committee to Justice Health on Hepatitis C Care and Treatment Victoria
WHO Advisor –Think tank to develop strategies to eliminate hepatitis B and C
WHO Advisor – Hepatitis C Surveillance and Screening
WHO Temporary Advisor - WHO Consultation on Strategic use of ARVs
WHO Temporary Advisor – WHO Consultation on Hepatitis C Modelling
Communicable Diseases Network of Australia National Strategies BBV/STI Subcommittee
InC3 – International Collaboration of Incidence Hepatitis C in Injection Drug users (coordinating committee).
Australian Hepatitis Councils Health Reference Group
Victorian Department of Health Advisory Committee on BBVs and STIs
ASHM Viral Hepatitis Clinical Oversight Committee

Qualifications

2001: FAFPHM, Australasian Faculty of Public Health Medicine
2000: PhD, Department of Epidemiology and Preventive Medicine, Monash University
1996: FRACP, Royal Australasian College of Physicians
1986: MBBS, Monash University

Awards

2019: Member of the Order of Australia (AM) ‘for significant service to medicine as an infectious diseases and public health physician and research scientist’.
2010: Burnet Institute Frank Fenner Award: Recognised for her outstanding leadership, innovation and contribution to the fields of research and public health
2005: Victorian Public Health Award, Program excellence winner for HIV sentinel surveillance
2005: VicHealth Award for Outstanding Achievement in Health Promotions (studies over $75,000) for The epidemiology and control of chlamydia infection in Victoria
2005: VicHealth Award for Outstanding Achievement in Health Promotions (studies less than $15,000) for Uncontested possessions and key positions
2005: Frank Fenner Award for Advanced Research in Infectious Diseases
2004: NHMRC Career Development Award
2004: VicHealth Senior Research Fellowship
2001: Australasian Society of Infectious Diseases, Aztra Zeneca Travel Award
2000: Inaugural Graham Rouch Award, Victorian Branch of the Australasian Faculty of Public Health Medicine
2000: Young Water Scientist of the Year
2000: Victorian Public Health Award for Research Excellence
2000: NHMRC Clinical Research Fellowship
1998: NHMRC Clinical Research Fellowship

Projects (52)

Current (33)

ACCESS: The Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood Borne Viruses and Sexually Transmitted Infections
Cancer information compared to Hepatitis B information to INcreAse hepatitis B testing in Melbourne’s Chinese community (CHINA-B study)
COVASIM: Modelling COVID-19
DARE C: ATAHC II Substudy
EC Australia: Eliminate Hepatitis C Australia Partnership
EC Partnership: Eliminate Hepatitis C Partnership
Exploring alcohol and other drug use among migrant communities in Victoria
Feasibility and Outcomes of the Public Sector Hepatitis C Treatment Program in Myanmar
HCV Elimination Modelling
Healthy Mothers, Healthy Babies
Hepatitis B Modelling
Hepatitis C and injecting networks
Hepatitis C brief reports
Hepatitis C: Community Testing and Treatment (CT2)
Identifying the structural enablers to the clinical management of people with hepatitis B in general practice: a qualitative investigation
Improving Hepatitis B Virus screening in general practice in Victoria
Modelling hepatitis C virus elimination and control policies in Myanmar
Natural history and response to treatment recent hepatitis C virus infection among a cluster of HCV genotype-1b infected individuals
Optimising Quarantine Study
Pornography and Young People
Sex, Drugs, and Rock'n'Roll (Big Day Out Study)
SHARP: Screening for Hepatitis in At-Risk Populations
Social Networks and the Hepatitis C Virus
The Australian Trial in Acute Hepatitis C (ATAHC)
The B-VAX Project: Hep B vaccinations for people who inject drugs
The elimination of hepatitis C as a global public health threat
The International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)
The Optimise Study: Optimising Isolation, Quarantine and Distancing for COVID-19
The QuickStart Study
TRYP: Transitions and Risk in Young People project
Understanding how HCV evades the immune system
VOICE - Victorian Online Initiative for Community Engagement
What drives hepatitis C reinfection?

Past (3)

co-EC Study: Eliminating hepatitis C/HIV coinfection
Eliminating hepatitis C infection in Victoria through treatment scale up
Examining hepatitis C reinfection among HIV co-infected gay and bisexual men

Publications (540)

2022 (29)

Constructing a 'target population': A critical analysis of public health discourse on substance use among gay and bisexual men, 2000-2020.
Schroeder SE, Bourne A, Doyle JS, Hellard ME, Stoové M, Pedrana A
Int J Drug Policy. 2022 Jul; 108:103808
"You have to drink with a little bit of shame": Alcohol and other drug use among young people from migrant and ethnic minority backgrounds in Melbourne, Australia.
Douglass CH, Block K, Eghrari D, Horyniak D, Hellard ME, Lim MSC
J Ehn Subst Abuse. 2022 Jun; Epub ahead of print
The impact of COVID-19 on public health systems in the Pacific Island Countries and Territories.
Bell L, van Gemert C, Merilles OE Jr, Cash HL, Stoové M, Hellard M
Lancet Reg Health West Paci. 2022 Jun; 25(100498)
Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs.
Traeger MW, van Santen DK, Sacks-Davis R, Asselin J, Carter A, Doyle JS, Pedrana A, Wilkinson AL, Howell J, Thatcher R, Didlick J, Donovan B, Guy R, Hellard ME, Stoové MA; Australia Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmissible Infections and Blood Borne Viruses (ACCESS).
J Viral Hepat. 2022 Jun; Epub ahead of print
The impact of three progressively introduced interventions on second wave daily COVID-19 case numbers in Melbourne, Australia.
Saul A, Scott N, Spelman T, Crabb BS, Hellard M
BMC Infect Dis. 2022 Jun; 22(1):514
A survey of knowledge, attitudes, barriers and support needs in providing hepatitis B care among GPs practising in Australia.
Xiao Y, van Gemert C, Howell J, Wallace J, Richmond J, Adamson E, Thompson A, Hellard M
BMC Prim Care. 2022 Jun; 23(1):137
Latent Class Analysis of Sexual Behaviours and Attitudes to Sexually Transmitted Infections Among Gay and Bisexual Men Using PrEP.
Traeger MW, Murphy D, Ryan KE, Asselin J, Cornelisse VJ, Wilkinson AL, Hellard ME, Wright EJ, Stoové MA
AIDS Behav. 2022 Jun; 26(6):1808-1820
Evaluating the potential cost-effectiveness of microarray patches to expand access to hepatitis B birth dose vaccination in low-and middle-income countries: A modelling study.
Seaman CP, Mvundura M, Frivold C, Morgan C, Jarrahian C, Howell J, Hellard M, Scott N
PLoS Glob Pub Health. 2022 May; 2(5):e0000394
Feasibility of decentralised, task-shifted hepatitis C testing and treatment services in urban Myanmar: implications for scale-up.
Draper BL, Yee WL, Shilton S, Bowring A, Htay H, Nwe N, Markby J, Kyi KP, Easterbrook P, Naing W, Win TM, Aung KS, Howell J, Pedrana A, Hellard M
BMJ Open. 2022 May; 12(5):e059639
The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
Howell J, Traeger MW, Williams B, Layton C, Doyle JS, Latham N, Draper B, Bramwell F, Membrey D, McPherson M, Roney J, Stoové M, Thompson AJ, Hellard ME, Pedrana A
J Viral Hepat. 2022 May; 29(5):375-384
Mathematical Modeling for Removing Border Entry and Quarantine Requirements for COVID-19, Vanuatu.
van Gemert C, Tarivonda L, Tapo PS, Natuman S, Clark G, Mariasua J, Scott N, Craig A, Abel M, Cornish MJ, Hellard M, Sacks-Davis R
Emerg Infect Dis. 2022 May; 28(5):1053-1055
Hepatitis C antibody testing among opioid agonist therapy recipients, Victoria, Australia, 2012 to 2020.
Dawe J, Wilkinson AL, Asselin J, Carter A, Pedrana A, Traeger MW, Thomas AJ, Curtis M, Cooper M, Howell J, Doyle JS, Hellard ME, Stoové M; EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of blood borne viruses and sexually transmissible infections (ACCESS).
Int J Drug Policy. 2022 Apr; 104:103696
Hepatitis B and pregnancy: understanding the experiences of care among pregnant women and recent mothers in metropolitan Melbourne.
Ahad M, Wallace J, Xiao Y, van Gemert C, Bennett G, Darby J, Desmond P, Hall S, Holmes J, Papaluca T, Glasgow S, Thompson A, Hellard M, Doyle J, Howell J
BMC Public Health. 2022 Apr; 22(1):817
COVID-19 vaccine wastage in the midst of vaccine inequity: causes, types and practical steps.
Lazarus JV, Abdool Karim SS, van Selm L, Doran J, Batista C, Ben Amor Y, Hellard M, Kim B, Kopka CJ, Yadav P
BMJ Glob Health. 2022 Apr; 7(4)
Randomised controlled trial of active case management to link hepatitis C notifications to treatment in Tasmania, Australia: a study protocol.
Marukutira T, Moore KP, Hellard M, Richmond J, Turner K, Pedrana AE, Melody S, Johnston FH, Owen L, Van Den Boom W, Scott N, Thompson A, Iser D, Spelman T, Veitch M, Stoové MA, Doyle J
BMJ Open. 2022 Mar; 12(3):e056120
Hepatitis C incidence among patients attending primary care health services that specialise in the care of people who inject drugs, Victoria, Australia, 2009 to 2020.
Wilkinson AL, van Santen DK, Traeger MW, Sacks-Davis R, Asselin J, Scott N, Harney BL, Doyle JS, El-Hayek C, Howell J, Bramwell F, McManus H, Donovan B, Stoové M, Hellard M, Pedrana A
Int J Drug Policy. 2022 Mar; 103:103655
Understanding how to live with hepatitis B: a qualitative investigation of peer advice for Chinese people living with hepatitis B in Australia.
Wallace J, Xiao Y, Howell J, Thompson A, Allard N, Adamson E, Richmond J, Hajarizadeh B, Eagle M, Doyle J, Hellard M
BMC Public Health. 2022 Mar; 22(1):536
Making child's play of tolerance: Defining the immune-viral interplay during combination entecavir and pegylated interferon therapy for immune tolerant hepatitis B infection.
Howell J, Hellard M
Hepatology. 2022 Mar; Epub ahead of print
Preventing a cluster from becoming a new wave in settings with zero community COVID-19 cases.
Abeysuriya RG, Delport D, Stuart RM, Sacks-Davis R, Kerr CC, Mistry D, Klein DJ, Hellard M, Scott N
BMC Infect Dis. 2022 Mar; 22(1):232
"It's not just the hit itself": the social practice of injecting drug use among gay and bisexual men in Australia.
Schroeder SE, Bourne A, Doyle J, Stoove M, Hellard M, Pedrana A
Int J Drug Policy. 2022 Mar; 103:103642
Reducing liver disease-related deaths in the Asia-Pacific: the important role of decentralised and non-specialist led hepatitis C treatment for cirrhotic patients.
Draper B, Yee WL, Pedrana A, Kyi KP, Qureshi H, Htay H, Naing W, Thompson AJ, Hellard M, Howell J
Lancet Reg Health West Pac. 2022 Mar; 20:100359
Intent to Be Vaccinated against COVID-19 in Victoria, Australia.
Heath K, Altermatt A, Saich F, Pedrana A, Fletcher-Lartey S, Bowring AL, Stoové M, Danchin M, Kaufman J, Gibney KB, Hellard M
Vaccines (Basel). 2022 Jan; 10(2)
Exploring stigma associated with mental health conditions and alcohol and other drug use among people from migrant and ethnic minority backgrounds: a protocol for a systematic review of qualitative studies.
Douglass CH, Lim MSC, Block K, Onsando G, Hellard M, Higgs P, Livingstone C, Horyniak D
Syst Rev. 2022 Jan; 11(1):12
Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study).
O'Keefe D, Gunn J, Ryan K, Djordjevic F, Kerr P, Gold J, Elsum I, Layton C, Chan K, Dietze P, Higgs P, Doyle J, Stoové MA, Hellard M, Pedrana AE
BMJ Open. 2022 Jan; 12(1):e057618
Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
Mohamed Z, Scott N, Nayagam S, Rwegasha J, Mbwambo J, Thursz MR, Brown AS, Hellard M, Lemoine M
Int J Drug Policy. 2022 Jan; 99:103458
The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.
Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP
Lancet. 2022 Jan; 399(10319):61-116
Assessment of the cost-effectiveness of Australia’s risksharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study.
Scott N, Palmer A, Tidhar T, Stoové M, Sacks-Davis R, Doyle JS, Pedrana A, Thompson AJ, Wilson DP, Hellard M
Lancet Reg Health - West Pac. 2022 Jan; 18:100316
Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019.
Wilkinson AL, Pedrana A, Traeger MW, Asselin J, El-Hayek C, Nguyen L, Polkinghorne V, Doyle JS, Thompson AJ, Howell J, Scott N, Dimech W, Guy R, Hellard M, Stoové M; EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of blood borne viruses and sexually transmissible infections (ACCESS)
Epidemiol Infect. 2022 Jan; 150:e7
The Incidence of Hepatitis C Among Gay, Bisexual, and Other Men Who Have Sex With Men in Australia, 2009-2019.
Harney BL, Sacks-Davis R, van Santen DK, Traeger M, Wilkinson AL, Asselin J, El-Hayek C, Fairley CK, Roth N, Bloch M, Matthews G, Donovan B, Guy R, Stoové M, Hellard ME, Doyle JS; Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmissible Infections and Blood-borne Viruses (ACCESS).
Clin Infect Dis. 2022 Jan; 74(10):1804-1811

2021 (50)

Assessing the feasibility, acceptability and impacts of an education program on hepatitis B testing uptake among ethnic Chinese in Australia: results of a randomised controlled pilot study.
Xiao Y, Wallace J, Ahad M, van Gemert C, Thompson AJ, Doyle J, Lam HY, Chan K, Bennett G, Adamson E, Yussf N, Tang A, Pedrana A, Stoove M, Hellard M, Howell J
BMC Public Health. 2021 Oct; 21(1):1861
Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis.
Lim AG, Scott N, Walker JG, Hamid S, Hellard M, Vickerman P
PLoS Med. 2021 Oct; 18(10):e1003818
Letter in response: Psychiatrists can treat hepatitis C.
Harney BL, Brereton R, Whitton B, Pietrzak D, Paige E, Roberts SK, Birks S, Saraf S, Hellard ME, Doyle JS
J Viral Hepat. 2021 Sep; 28(12):1765+1766
Modelling the Victorian roadmap (PUBLIC HEALTH REPORT)
Abeysuriya R, Delport D, Sacks-Davis R, Hellard M, Scott N
Know-C19. 2021 Sep; September:1-23
Health service utilisation and experiences of stigma among people who inject drugs in Melbourne, Australia.
Djordjevic F, Ryan K, Gunn J, Brener L, O'Keefe D, Draper B, Schroeder S, Gold J, Treloar C, Broady T, Dietze P, Hellard M, Pedrana A
J Viral Hepat. 2021 Sep; 28(12):1738-1743
A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
Palmer AY, Chan K, Gold J, Layton C, Elsum I, Hellard M, Stoove M, Doyle JS, Pedrana A, Scott N; EC Partnership
J Viral Hepat. 2021 Aug; 28(11):1624-1634
Routine testing for syphilis and other bacterial sexually transmissible infections is required among people in prison.
Harney B, Doyle J, Hellard M, Stoové M, Winter R
Sex Transm Dis. 2021 Aug; 48(10):e153
The Optimise Study: Vaccination knowledge, attitudes and beliefs. (PUBLIC HEALTH REPORT)
Saich F, Kwong E, Heath K, Altermatt A, Munari S. Merner B, Hill S, Stoové M, Griffiths D, Collie A, Lim M, Eddy S, Meagher N, McDougall C, Marinkovic Chavez K, Carpenter L, Fletcher-Lartey S, Price D, Gibbs L, Shearer F, Power R, Cheong M, Caddy C, Pedrana A, Gibney K, Hellard M
Optimise Study. 2021 Aug; Report 9:1-15
The introduction of a mandatory mask policy was associated with significantly reduced COVID-19 cases in a major metropolitan city.
Scott N, Saul A, Spelman T, Stoove M, Pedrana A, Saeri A, Grundy E, Smith L, Toole M, McIntyre CR, Crabb BS, Hellard M
PLoS One. 2021 Jul; 16(7):e0253510
Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV.
Lazarus JV, Safreed-Harmon K, Kamarulzaman A, Anderson J, Leite RB, Behrens G, Bekker LG, Bhagani S, Brown D, Brown G, Buchbinder S, Caceres C, Cahn PE, Carrieri P, Caswell G, Cooke GS, Monforte AD, Dedes N, Del Amo J, Elliott R, El-Sadr WM, Fuster-Ruiz de Apodaca MJ, Guaraldi G, Hallett T, Harding R, Hellard M, Jaffar S, Kall M, Klein M, Lewin SR, Mayer K, Pérez-Molina JA, Moraa D, Naniche D, Nash D, Noori T, Pozniak A, Rajasuriar R, Reiss P, Rizk N, Rockstroh J, Romero D, Sabin C, Serwadda D, Waters L
Nat Commun. 2021 Jul; 12(1):4450
Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study.
Goutzamanis S, Horyniak D, Doyle JS, Hellard M, Higgs P; Treatment and Prevention Study group
Harm Reduct J. 2021 Jul; 18(1):73
COVID-19 NSW outbreak (PUBLIC HEALTH REPORT)
Scott N, Hellard M, Abeysuriya R
Know-C19 Public Health Report. 2021 Jul
The Optimise Study: Impact of government restrictions on risk mitigation strategies. (PUBLIC HEALTH REPORT)
Saich F, Kwong E, Heath K, Altermatt A, Munari S. Merner B, Hill S, Power R, Cheong M, Caddy C, Griffiths D, Collie A, Stoové M, Pedrana A, Gibney K, Hellard M
Optimise Study. 2021 Jul; Report 8:1-12
Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study.
Olafsson S, Fridriksdottir RH, Love TJ, Tyrfingsson T, Runarsdottir V, Hansdottir I, Bergmann OM, Björnsson ES, Johannsson B, Sigurdardottir B, Löve A, Baldvinsdottir GE, Hernandez UB, Gudnason T, Heimisdottir M, Hellard M, Gottfredsson M
Lancet Gastroenterol Hepatol. 2021 Jun; 6(8):628-637
Outcomes of the CT2 Study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar.
Draper B, Htay H, Pedrana A, Yee WL, Howell J, Kyi KP, Naing W, Aung KS, Markby J, Easterbrook P, Bowring A, Aung W, Sein YY, Nwe N, Myint KT, Shilton S, Hellard M
Liver Int. 2021 Jun; 41(11):2578-2589
COVASIM modelling: Impact of vaccines on epidemic outcomes. (PUBLIC HEALTH REPORT)
Abeysuriya R, Hellard M, Scott N
Know-C19. 2021 Jun; June:1-2
Implications of HIV self-testing for other sexually transmissible infection testing and broader sexual health needs: a mixed methods study of gay and bisexual men in Australia.
Leitinger D, Ryan K, Wilkinson AL, Pedrana A, Hellard M, Stoové M
Sex Transm Dis. 2021 Jun; 48(6):417-423
The Optimise Study: The impact of COVID19 on income and finances. (PUBLIC HEALTH REPORT)
Saich F, Kwong E, Heath K, Altermatt A, Munari S. Merner B, Hill S, Griffiths D, Collie A, Stoové M, Pedrana A, Gibney K, Hellard M
Optimise Study. 2021 Jun; Report 7:1-9
A qualitative exploration of enablers for hepatitis B clinical management among ethnic Chinese in Australia.
Xiao Y, Wallace J, Thompson A, Hellard M, van Gemert C, Holmes JA, Croagh C, Richmond J, Papaluca T, Hall S, Hong T, Demediuk B, Iser D, Ryan M, Desmond P, Visvanathan K, Howell J
J Viral Hepat. 2021 Jun; 28(6):925-933
"It's time!": A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C.
Walker S, Wallace J, Latham N, Saich F, Pedrana A, Hellard M, Treloar C, Marukutira T, Higgs P, Doyle J, Stoové M
Int J Drug Policy. 2021 May; 97:103280
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, Thurnheer C, Bruneau J, Kim A, Hellard M, Shaw D, Gane E, Nelson M, Ingiliz P, Applegate TL, Grebely J, Marks P, Martinello M, Petoumenos K, Dore GJ; REACT study group; Protocol Steering Committee, van der Valk M, Hellard M, Gane E, Rauch A, Bruneau J, Kim A, Bhagani S, Dore G, Marks P, Matthews G, Grebely J, Petoumenos K, Martinello M, Applegate T, Feld J, Rockstroh J; Coordinating Centre; Site Principal Investigators.
J Hepatol. 2021 May; 75(4):829-839
Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits.
Scott N, Win TM, Tidhar T, Htay H, Draper B, Aung PTZ, Xiao Y, Bowring A, Kuschel C, Shilton S, Kyi KP, Naing W, Aung KS, Hellard M
Lancet Reg Health West Pac. 2021 May; 10:100129
The Optimise Study: Gendered differences in coping and responding to COVID-19. (PUBLIC HEALTH REPORT)
Saich F, Kwong E, Heath K, Altermatt A, Munari S. Merner B, Hill S, Stoové M, Pedrana A, Gibney K, Hellard M
Optimise Study. 2021 May; Report 6:1-10
Role of masks, testing and contact tracing in preventing COVID-19 resurgences: a case study from New South Wales, Australia
Stuart RM, Abeysuriya RG, Kerr CC, Mistry D, Klein DJ, Gray RT, Hellard M, Scott N
BMJ Open. 2021 Apr; 11(4):e045941
Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
Goutzamanis S, Spelman T, Harney B, Dietze P, Stoové M, Higgs P, Thompson A, Doyle JS, Hellard M; Treatment, Prevention Study group.
J Viral Hepat. 2021 Apr; 28(7):1068-1077
Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs.
Cunningham EB, Hajarizadeh B, Amin J, Hellard M, Bruneau J, Feld JJ, Cooper C, Powis J, Litwin AH, Marks P, Dalgard O, Conway B, Moriggia A, Stedman C, Read P, Bruggmann P, Lacombe K, Dunlop A, Applegate TL, Matthews GV, Fraser C, Dore GJ, Grebely J
Clin Infect Dis. 2021 Apr; 72(8):1392-1400
Affordable treatment and political commitment are crucial to eliminate hepatitis C globally.
Hellard M, Pedrana A, Draper B
Lancet Gastroenterol Hepatol. 2021 Apr; 6(6):414-416
Addressing alcohol and other drug use among young people from migrant and ethnic minority backgrounds: Perspectives of service providers in Melbourne, Australia.
Douglass CH, Block K, Horyniak D, Hellard ME, Lim MSC
Health Soc Care Community. 2021 Apr; 29(6):e308-e317
The Optimise Study: Social networks and mixing patterns. (PUBLIC HEALTH REPORT)
Saich F, Heath K, Altermatt A, Munari S, Merner B, Hill S, Lusher D, Radhitio Sadewo G, Wang P, Pedrana A, Gibney K, Hellard M
The Optimise Study. 2021 Apr; Report 5:1-12
Tuberculosis in migrants to Australia: Outcomes of a national screening program.
Trauer JM, Williams B, Laemmie-Ruff I, Horyniak D, Soares Caplice LV, McBrtde ES, Majumdar SS, Graem SM, Hellard ME
Lancet Reg Health - West Pac. 2021 Mar; 10:100135
Low incidence of hepatitis C among a cohort of HIV-negative gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Melbourne, Australia, and the contribution of sexual transmission.
Cornelisse VJ, Traeger MW, Wright EJ, Murphy D, Stoove M, Hellard M, Sacks-Davis R, Asselin J, Fairley CK, Doyle J, Sasawdeusz J
J Acquir Immune Defic Syndr. 2021 Mar; 87(4):1011-1015
A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison.
Palmer A, Papaluca T, Stoové M, Winter R, Pedrana A, Hellard M, Wilson D, Thompson A, Scott N; EC Victoria Partnership.
Int J Drug Policy. 2021 Mar; 94:103203
Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale-up of direct-acting antiviral treatment.
Palmer AY, Wilkinson A, Aitken C, Dietze P, Dore GJ, Maher L, Sacks-Davis R, Stoové M, Wilson D, Hellard M, Scott N
J Gastroenterol Hepatol. 2021 Mar; 36(8):2270-2274
A Systematic Review of Interventions Used to Increase Blood Donor Compliance with Deferral Criteria.
Cutts JC, Quinn B, Seed CR, Kotsiou G, Pearson R, Scott N, Wilson DP, Harrod ME, Maher L, Caris S, Thompson AJ, Farrell M, Pink J, Hellard ME
Transfus Med Hemother. 2021 Mar; 48(2):118-129
The Optimise Study: Vaccine preparedness. (PUBLIC HEALTH REPORT)
Saich F, Heath K, Altermatt A, Merner B, Hill S, Pedrana A, Munari S, Horyniak D, Walker S, Wallace J, Block K, Gibbs L, Gibney K, Hellard M
Optimise Study. 2021 Mar; Report 4:1-8
A global investment framework for the elimination of hepatitis B.
Howell J, Pedrana A, Schroeder SE, Scott N, Aufegger L, Atun R, Baptista-Leite R, Hirnschal G, Hoen E', Hutchinson SJ, Lazarus JV, Olufunmilayo L, Peck R, Sharma M, Sohn AH, Thompson A, Thursz M, Wilson D, Hellard M
J Hepatol. 2021 Mar; 74(3):535-549
Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care.
Harney BL, Brereton R, Whitton B, Pietrzak D, Paige E, Roberts SK, Birks S, Saraf S, Hellard ME, Doyle JS
J Viral Hepat. 2021 Feb; 28(5):771-778
A New Method for Estimating the Incidence of Infectious Diseases.
McManus H, Callander D, Asselin J, McMahon J, Hoy JF, Templeton DJ, Fairley CK, Donovan B, Pedrana AE, Keen P, Wilson DP, Elliott J, Kaldor J, Liaw ST, Petoumenos K, Holt M, Hellard ME, Grulich AE, Carr A, Stoové MA, Guy RJ
Am J Epidemiol. 2021 Feb; 190(7):1386-1395
Modelling the impact of reducing control measures on the COVID-19 pandemic in a low transmission setting.
Scott N, Palmer A, Delport D, Abeysuriya R, Stuart R, Kerr CC, Ministry D, Klein D, Sacks-Davis R, Heath K, Hainsworth S, Pedrana A, Stoové M, Wilson D, Hellard ME
Med J Aust. 2021 Feb; 214(2):79-83
Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: A cost-effectiveness model.
Scott N, Mohamed Z, Rwegasha J, Mbwambo J, Lemoine M, Hellard M
Int J Drug Policy. 2021 Feb; 88:102634
Changes in HIV preexposure prophylaxis prescribing in Australian clinical services following COVID-19 restrictions.
Traeger MW, Patel P, Guy R, Hellard ME, Stoové MA for the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS)
AIDS. 2021 Jan; 35(1):155-157
In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care.
Wade AJ, Doyle JS, Draper B, Howell J, Iser D, Roberts SK, Kemp W, Thompson AJ, Hellard ME
J Viral Hepat. 2021 Jan; 28(1):217-218
The phases of hepatitis C elimination: achieving WHO elimination targets.
Pedrana A, Munari S, Stoové M, Doyle J, Hellard M
Lancet Gastroenterol Hepatol. 2021 Jan; 6(1):6-8
Matching action to need: an analysis of Global Burden of Disease 2017 and population health data to focus adolescent health policy and actions in Myanmar.
Cini KI, Win PM, Swe ZY, Than KK, Win TM, Aung YW, Myint AA, Wulan NR, Burns LJ, Kennedy EC, Francis KL, Sanda, Myat SM, Swe S, Ko AK, Yadanar, Hellard M, Hughes CL, Patton GC, Mokdad AH, Azzopardi PS
Glob Health Action. 2021 Jan; 14(1):1844976
Letter to the Editor: Recommendations for implementing hepatitis C virus care in homeless shelters: The stakeholder perspective.
Harney B, McColl R, Pedrana A, Morrison E, Doyle J, Hellard M, Higgs P
Hepatol Commun. 2021 Jan; 5(1):146-147
Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia.
Chan K, Elsum I, Gold J, Layton C, Accadia L, Bryant M, Gunn J, Djordjevic F, Purcell I, Dicka J, Forrest M, Crawford S, Hellard M, Pedrana A; Eliminate Hepatitis C Partnership
J Viral Hepat. 2021 Jan; 28(3):569-572
Peer to peer communication about hepatitis C treatment amongst people who inject drugs: A longitudinal qualitative study.
Goutzamanis S, Doyle JS, Horyniak D, Higgs P, Hellard M; TAP study group
Int J Drug Policy. 2021 Jan; 87:102983
‘Not my child’: parenting, pornography, and views on education.
Davis AC, Wright C, Curtis M, Hellard ME, Lim MSC, Temple-Smith MJ
J Fam Studies. 2021 Jan; 27(4):573-588
Micro-elimination of hepatitis C among people with HIV coinfection: declining incidence and prevalence accompanying a multi-center treatment scale-up trial.
Doyle JS, van Santen DK, Iser D, Sasadeusz J, O'Reilly M, Harney B, Traeger MW, Roney J, Cutts JC, Bowring AL, Winter R, Medland N, Fairley CK, Moore R, Tee B, Asselin J, El-Hayek C, Hoy JF, Matthews GV, Prins M, Stoové MA, Hellard ME
Clin Infect Dis. 2021 Jan; 73(7):e2164–e2172
Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics.
Papaluca T, Roberts SK, Strasser SI, Stuart KA, Farrell G, MacQuillan G, Dore GJ, Wade AJ, George J, Hazeldine S, O'Beirne J, Wigg A, Fisher L, McGarity B, Sawhney R, Sinclair M, Thomas J, Valiozis I, Weltman M, Wilson M, Woodward A, Ahlenstiel G, Haque M, Levy M, Prewett E, Sievert W, Sood S, Tse E, Valaydon Z, Bowden S, Douglas M, New K, O'Keefe J, Hellard M, Doyle J, Stoové M, Thompson AJ
Clin Infect Dis. 2021 Jan; 73(9):e3288-e3295

2020 (50)

Effect of a mobile phone intervention for female sex workers on unintended pregnancy in Kenya (WHISPER or SHOUT): a cluster-randomised controlled trial.
Ampt FH, Lim MSC, Agius PA, L'Engle K, Manguro G, Gichuki C, Gichangi P, Chersich MF, Jaoko W, Temmerman M, Stoové M, Hellard M, Luchters S
Lancet Glob Health. 2020 Dec; 8(12):e1534-e1545
Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.
Papaluca T, Craigie A, McDonald L, Edwards A, MacIsaac M, Holmes JA, Jarman M, Lee T, Huang H, Chan A, Lai M, Sundararajan V, Doyle JS, Hellard M, Stoove M, Howell J, Desmond P, Iser D, Thompson A
PLoS One. 2020 Nov; 15(11):e0242101
Impact of Victoria's Stage 3 lockdown on COVID-19 case numbers
Saul A, Scott N, Crabb BS, Majumdar SS, Coghlan B, Hellard ME
MJA. 2020 Nov; 213(11):494-496
A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C.
Ramsay J, Marsh J, Pedrana A, Andric N, Norman R, Cheng W, Webb S, Zeps N, Bellgard M, Graves T, Hellard M, Snelling T
BMC Infect Dis. 2020 Oct; 20(1):802
HIV infections among female sex workers in Mombasa, Kenya: current prevalence and trends over 25 years.
Manguro GO, Gichuki C, Ampt FH, Agius PA, Lim MS, Jaoko WG, Hellard M, L'Engle K, Stoové M, Mandaliya K, Chersich MF, Temmerman M, Luchters S, Gichangi P
Int J STD AIDS. 2020 Oct; 31(14):1389-1397
Estimating risks associated with early reopening in Victoria. (Policy Brief prepared for the Victorian Department of Health and Human Services)
Abeysuriya R, Delport D, Hellard M, Scott N
Know-C19 Hub. 2020 Sep
Authors' response to Letter to the Editor: "Colombian experience in the management of hepatitis C".
Schroeder S, Pedrana A, Scott N, Hellard M
Liver Int. 2020 Sep; 40(12):3142-3143
Facilitating hepatitis B clinical management in general practice: A qualitative investigation.
Wallace J, Richmond J, Allard N, Howell J, Adamson E, XiaoYZ, O’Reilly C, Hellard M
Aust J Gen Pract. 2020 Sep; 49(9):599-604
Phylogenetic clustering networks among heterosexual migrants with new HIV diagnoses post-migration in Australia.
Sacks-Davis R, Chibo D, Peach E, Aleksic E, Crowe SM, El Hayek C, Marukutira T, Higgins N, Stoové M, Hellard M
PLoS One. 2020 Sep; 15(9):e0237469
Validation of the TREAT-B score for hepatitis B treatment eligibility in a large Asian cohort: TREAT-B improves with age.
Howell J, Anderson D, Bloom S, Lubel J, Kemp W, Williams J, Bell S, Croagh C, Demediuk B, Desmond P, Hall S, Holmes J, Hong T, Iser D, Lim L, Papaluca T, Ryan M, Visvanathan K, Xiao Y, van Gemert C, Hellard M, Thompson A
J Hepatol. 2020 Sep; 73(5):1282-1284
The impact of markers of HIV infection on change in liver stiffness in people with HIV and hepatitis C virus co-infection after treatment and cure of hepatitis C.
van Santen DK, Agius PA, Sasadeusz J, Fairley KC, Sievert W, Gane E, Iser D, O'Reilly M, Medland NA, Moore R, Hellard ME, Hoy JF, Doyle JS
J Acquir Immune Defic Syndr. 2020 Aug; 85(5):e81-e89
Estimates of the global reduction in liver disease-related mortality with increased coffee consumption: an analysis of the Global Burden of Disease Dataset.
Gow P, Spelman T, Gardner S, Hellard M, Howell J
Aliment Pharmacol Ther. 2020 Aug; 52(7):1195-1203
A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available.
Gooey M, Wong E, Pedrana A, Allard N, Doyle J, Hellard M, Wade A
Sex Health. 2020 Aug; 17(4):387-389
Closing the stable door after the horse has bolted - should we be treating people with immune-tolerant chronic hepatitis B to prevent hepatocellular carcinoma?
Howell J, Chan HL, Feld JJ, Hellard ME, Thompson AJ
Gastroenterology. 2020 Aug; 158(8):2028-2032
Global hepatitis C elimination: an investment framework.
Pedrana A, Howell J, Scott N, Schroeder S, Kuschel C, Lazarus JV, Atun R, Baptista-Leite R, 't Hoen E, Hutchinson SJ, Aufegger L, Peck R, Sohn AH, Swan T, Thursz M, Lesi O, Sharma M, Thwaites J, Wilson DP, Hellard M
Lancet Gastroenterol Hepatol. 2020 Jul; 5(10):927-939
A model of the economic benefits of global hepatitis C elimination: an investment case.
Scott N, Kuschel C, Pedrana A, Schroeder S, Howell J, Thompson A, Wilson DP, Hellard M
Lancet Gastroenterol Hepatol. 2020 Jul; 5(10):940-947
Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S, Martinello M, Yee J, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle JS, Shaw D, Hellard M, Petoumenos K, Carson J, Dore GJ, Matthews GV; CEASE study team
AIDS. 2020 Jul; 34(9):1347-1358
Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study.
Draper BL, Pedrana A, Howell J, Yee WL, Htay H, Aung KS, Shilton S, Kyi KP, Naing W, Hellard M
JMIR Res Protoc. 2020 Jul; 9(7):e16863
The potential impact of a gel-based point-of-sex intervention in reducing gonorrhoea incidence among gay and bisexual men: a modelling study.
Traeger MW, Tidhar T, Holt M, Williams C, Wright EJ, Stoové MA, Scott N, Hellard ME
Sex Transm Dis. 2020 Jul; 47(10):649-657
Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study.
Seaman CP, Morgan C, Howell J, Xiao Y, Spearman CW, Sonderup M, Lesi O, Andersson MI, Hellard ME, Scott N
Lancet Glob Health. 2020 Jul; 8(7):e931-e941
Hepatitis C elimination in people living with HIV - the importance of biomedical and behavioural interventions.
van Santen DK, Sacks-Davis R, Hellard M
J Int AIDS Soc. 2020 Jul; 23(7):e25589
The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
Traeger MW, Pedrana AE, van Santen DK, Doyle JS, Howell J, Thompson AJ, El-Hayek C, Asselin J, Polkinghorne V, Membrey D, Bramwell F, Carter A, Guy R, Stoové MA, Hellard ME; EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood-borne Viruses and Sexually Transmitted Infections (ACCESS)
PLoS One. 2020 Jun; 15(6):e0235445
Privacy-Preserving Record Linkage of Deidentified Records Within a Public Health Surveillance System: Evaluation Study.
Nguyen L, Stoové M, Boyle D, Callander D, McManus H, Asselin J, Guy R, Donovan B, Hellard M, El-Hayek C
J Med Internet Res. 2020 Jun; 22(6):e16757
Frequent occurrence of low-level positive autoantibodies in chronic hepatitis C.
Deshpande P, Bundell C, McKinnon E, Hellard M, Ffrench R, Wilkinson AL, Drummer H, Gaudieri S, Lucas M
Pathology. 2020 Jun; 52(5):576-583
A Mobile Phone-Based Sexual and Reproductive Health Intervention for Female Sex Workers in Kenya: Development and Qualitative Study.
Ampt FH, L'Engle K, Lim MSC, Plourde KF, Mangone E, Mukanya CM, Gichangi P, Manguro G, Hellard M, Stoové M, Chersich MF, Jaoko W, Agius PA, Temmerman M, Wangari W, Luchters S
JMIR Mhealth Uhealth. 2020 May; 8(5):e15096
Enhancing the hepatitis B care cascade in Australia: a cost-effectiveness model.
Xiao Y, Howell J, van Gemert C, Thompson AJ, Seaman CP, McCulloch K, Scott N, Hellard ME
J Viral Hepat. 2020 May; 27(5):526-536
A strategic framework to ease community-wide Covid-19 suppression measures.
Coghlan B, Majumdar SS, Pedrana A, Hellard ME, Crabb BS
MJA. 2020 Apr; Epub preprint
Trends in human immunodeficiency virus and sexually transmitted Infection testing among gay, bisexual, and other men who have sex with men after rapid scale-up of preexposure prophylaxis in Victoria, Australiaia.
Ryan KE, Asselin J, Fairley CK, Armishaw J, Lal L, Nguyen L, Murphy D, Traeger M, Hellard M, Hoy J, Stoové M, Wright E; PrEPX Study team
Sex Transm Dis. 2020 Apr; 47(8):516-552
Effectiveness of an Ecological Momentary Intervention for Reducing Risky Alcohol Consumption Among Young Adults: Protocol for a Three-Arm Randomized Controlled Trial.
Wright C, Dietze PM, Kuntsche E, Livingston M, Agius PA, Room R, Raggatt M, Hellard M, Lim MSC
JMIR Res Protoc. 2020 Mar; 9(3):e14190
Measuring hepatitis C virus elimination as a public health threat:beyond global targets.
van Santen DK, Sacks-Davis R, Doyle JS, Scott N, Prins M, Hellard M
J Viral Hepat. 2020 Mar; 27(8):770-773
Australia needs to increase testing to achieve hepatitis C elimination.
Scott N, Sacks-Davis R, Wade AJ, Stoové M, Pedrana A, Doyle JS, Thompson AJ, Wilson DP, Hellard ME
Med J Aust. 2020 Mar; 212(8):365-370
A digital pornography literacy resource co-designed with vulnerable young people: Development of "The Gist"
Davis AC, Wright CC, Murphy S, Dietze P, Temple-Smith MJ, Hellard ME, Lim MS
J Med Internet Res. 2020 Feb; 22(6):e15964
Point-of-care HIV testing can help achieve UNAIDS targets.
Hellard M, Ryan KE, Stoové M
Lancet HIV. 2020 Feb; 7(4):e216-e217
Blood donation amongst people who inject drugs in Australia: research supporting policy change.
Quinn B, Pearson R, Cutts J, Seed C, Scott N, Hoad V, Dietze P, Wilson D, Maher L, Thompson A, Farrell M, Harrod M, Caris S, Pink J, Kotsiou G, Hellard M
Vox Sang. 2020 Feb; 115(3):162-70
A quasi-experimental text messaging trial to improve adolescent sexual and reproductive health and smoking knowledge in Indonesia.
Pedrana AE, Pina J, Padmawati RS, Zuhrina R, Lazuardi L, Lim MSC, Hellard ME, Prabandari YS
Sex Health. 2020 Feb; 17(2):167-177
HIV pre-exposure prophylaxis for female sex workers: ensuring women's family planning needs are not left behind.
Bowring AL, Ampt FH, Schwartz S, Stoové MA, Luchters S, Baral S, Hellard M
J Int AIDS Soc. 2020 Feb; 23(2):e25442
A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment.
Palmer AY, Wade AJ, Draper B, Howell J, Doyle JS, Petrie D, Thompson AJ, Wilson DP, Hellard ME, Scott N
Int J Drug Policy. 2020 Feb; 76:102633
Prevalence of daily tobacco smoking participation among HIV-positive and HIV-negative Australian gay, bisexual and other men who have sex with men.
Wilkinson A, Quinn B, Draper B, White S, Hellard M, Stoové M
HIV Med. 2020 Feb; 21(2):e3-e4
Trends in late and advanced HIV diagnoses among migrants in Australia; implications for progress on Fast-Track targets: A retrospective observational study.
Marukutira T, Gunaratnam P, Douglass C, Jamil MS, McGregor S, Guy R, Gray RT, Spelman T, Horyniak D, Higgins N, Giele C, Crowe SM, Stoové M, Hellard M
Medicine. 2020 Feb; 99(8):e19289
Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection.
Scott N, Snell G, Westall G, Pilcher D, Raggatt M, Walker RG, Hellard M, Peleg AY, Doyle J
Sci Rep. 2020 Jan; 10(1):1459
Modelling the impact of migrants on the success of the HIV care and treatment program in Botswana.
Marukutira T, Scott N, Kelly SL, Birungi C, Makhema JM, Crowe S, Stoové M, Hellard M
PLoS One. 2020 Jan; 15(1):e0226422
'Think Hep B' in primary care: A before-and-after evaluation of a self-guided learning package.
Xiao Y, van Gemert C, Howell J, Adamson E, Towell V, Cowie BC, Thompson AJ, Hellard M
Aust J Gen Pract. 2020 Jan; 49(1-2):66-69
Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure.
Stoové M, Wallace J, Higgs P, Pedrana A, Goutzamanis S, Latham N, Scott N, Treloar C, Crawford S, Doyle J, Hellard M
Int J Drug Policy. 2020 Jan; 75:102596
Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection.
Geddes L, Iversen J, Wand H, Esmaeili A, Tsui J, Hellard M, Dore G, Grebely J, Dietze P, Bruneau J, Prins M, Morris MD, Shoukry NH, Lloyd AR, Kim AY, Lauer G, Cox AL, Page K, Maher L; InC3 Collaborative.
Clin Infect Dis. 2020 Jan; 70(1):123-131
A descriptive analysis of young women.
Davis AC, Temple-Smith MJ, Carrotte E, Hellard ME, Lim MSC
Sex Health. 2020 Jan; 17:69-76
The Elimination of Hepatitis C as a Public Health Threat.
Hellard M, Schroeder SE, Pedrana A, Doyle J, Aitken C
Cold Spring Harb Perspect Med. 2020 Jan; 10(4):a036939
Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies.
Artenie AA, Cunningham EB, Dore GJ, Conway B, Dalgard O, Powis J, Bruggmann P, Hellard M, Cooper C, Read P, Feld JJ, Hajarizadeh B, Amin J, Lacombe K, Stedman C, Litwin AH, Marks P, Matthews GV, Quiene S, Erratt A, Bruneau J, Grebely J
Clin Infect Dis. 2020 Jan; 70(11):2369–2376
Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study.
Martinello M, Yee J, Bartlett SR, Read P, Baker D, Post JJ, 7, 8, Finlayson R, Bloch M, Doyle J, Shaw D, Hellard M, Petoumenos K, Lin L, Marks P, Applegate T, Dore GJ, Matthews GV; CEASE study team
Clin Infect Dis. 2020 Jan; 71(6):1502-1510
Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs.
Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
Clin Infect Dis. 2020 Jan; 70(9):1900-1906
Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy.
Cunningham EB, Hajarizadeh B, Amin J, Litwin AH, Gane E, Cooper C, Lacombe K, Hellard M, Read P, Powis J, Dalgard O, Bruneau J, Matthews GV, Feld JJ, Dillon JF, Shaw D, Bruggmann P, Conway B, Fraser C, Marks P, Dore GJ, Grebely J
Clin Infect Dis. 2020 Jan; 71(7):E115-E124

2019 (37)

Retreatment with Elbasvir, Grazoprevir, Sofosbuvir +/- Ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
Papaluca T, Sinclair M, Gow P, Pianko S, Sievert W, Arachchi N, Cameron K, Bowden S, O'Keefe J, Doyle J, Stoove M, Hellard M, Iser D, Thompson A
Liver Int. 2019 Dec; 39(12):2285-2290
Hepatitis C.
Spearman CW, Dusheiko GM, Hellard M, Sonderup M
Lancet. 2019 Oct; 394(10207):1451-1466
Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia
Papalucaa T, .O’Keefe J, Bowden S, Doyle JS, Stoové M, Hellard M, Thompson AJ
J Clin Virol. 2019 Oct; 120:84-87
Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia.
Harney BL, Whitton B, Lim C, Paige E, McDonald B, Nolan S, Pemberton D, Hellard ME, Doyle JS
Int J Drug Policy. 2019 Oct; 72:195-198
Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
Williams B, Howell J, Doyle J, Thompson AJ, Draper B, Layton C, Latham N, Bramwell F, Membrey D, Mcpherson M, Roney J, Stoové M, Hellard ME, Pedrana A
Int J Drug Policy. 2019 Oct; 72:91-98
A comparative, retrospective analysis of HIV testing among gay, bisexual and other men who have sex with men in Melbourne, Australia.
Ryan KE, Wilkinson AL, Chow E, Read T, Chen M, Locke P, Leitinger D, Bradshaw C, Pedrana A, Hellard M, Fairley CK, Stoové M
Aust N Z J Public Health. 2019 Oct; 43(5):419-423
Risk of Subsequent HIV Infection Following Sexually Transmissible Infections Among Men Who Have Sex With Men.
Harney BL, Agius PA, El-Hayek C, Fairley CK, Chow EPF, Roth N, Tee BK, Leslie D, Tachedjian G, Hellard M, Stoové M
Open Forum Infect Dis. 2019 Oct; 6(10):ofz376
The case for a universal hepatitis C vaccine to achieve hepatitis C elimination.
Scott N, Wilson DP, Thompson AJ, Barnes E, El-Sayed M, Benzaken AS, Drummer HE, Hellard ME
BMC Med. 2019 Sep; 17(1):175
Gonorrhoea gone wild: rising incidence of gonorrhoea and associated risk factors among gay and bisexual men attending Australian sexual health clinics.
Callander D, Guy R, Fairley CK, McManus H, Prestage G, Chow EPF, Chen M, Connor CCO, Grulich AE, Bourne C, Hellard M, Stoové M, Donovan B
Sex Health. 2019 Sep; 16(5):457-463
Sexually transmissible infections among transgender men and women attending Australian sexual health clinics.
Callander D, Cook T, Read P, Hellard ME, Fairley CK, Kaldor JM, Vlahakis E, Pollack A, Bourne C, Russell DB, Guy RJ, Donovan B
Med J Aust. 2019 Aug; 211(9):406-411
A Health Education Website Developed to Meet Young People's Information Needs About Web-Based Pornography and Sharing of Sexually Explicit Imagery (SCOPE): Usability Study.
Davis AC, Wright CJC, Temple-Smith MJ, Hellard ME, Lim MSC
JMIR Form Res. 2019 Aug; 3(3):e12824
Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program.
Makuza JD, Liu CY, Ntihabose CK, Dushimiyimana D, Umuraza S, Nisingizwe MP, Umutesi J, Serumondo J, Mugeni SD, Semakula M, Gupta N, Hellard M, Nsanzimana S
BMC Infect Dis. 2019 Aug; 19(1):688
Assessment of service refinement and its impact on repeat HIV testing by client's access to Australia's universal healthcare system: a retrospective cohort study.
Ryan KE, Wilkinson AL, Asselin J, Leitinger DP, Locke P, Pedrana A, Hellard M, Stoové M
J Int AIDS Soc. 2019 Aug; 22(8):e25353
Excellence in Viral Hepatitis Elimination - Lessons from Georgia.
Averhoff F, Lazarus JV, Sergeenko D, Colombo M, Gamkrelidze A, Tsertsvadze T, Butsashvili M, Metreveli D, Sharvadze L, Hellard M, Gnes S, Gabunia T, Nasrullah M
J Hepatol. 2019 Jul; 71(4):645-647
Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing.
Abayasingam A, Leung P, Eltahla A, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Lloyd A, Rodrigo C
Infect Genet Evol. 2019 Jul; 71:36-41
Australia’s progress towards hepatitis C elimination. Annual Report 2019
Burnet Institute and Kirby Institute (Prepared by Wilkinson A, Edited by Margaret Hellard M, Stoové, M, Dore G, Grebely J, Pedrana A, Doyle J, Thompson A, Hajarizadeh B, Alavi M, Aitken C)
Annual Report. 2019 Jul
Clinical outcomes of a cohort of migrants and citizens living with human immunodeficiency virus in Botswana: implications for Joint United Nation Program on HIV and AIDS 90-90-90 targets.
Marukutira T, Yin D, Cressman L, Kariuki R, Malone B, Spelman T, Mawandia S, Ledikwe JH, Semo BW, Crowe S, Stoove M, Hellard M, Dickinson D
Medicine. 2019 Jun; 98(23):e15994
Pathology laboratory surveillance in the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) of sexually transmitted infections and blood borne viruses: Study Protocol.
van Gemert C, Guy R, Stoove M, Dimech W, El-Hayek C, Asselin J, Moreira C, Nguyen L, Callander D, Boyle D, Donovan B, Hellard M
J Med Internet Res. 2019 May; 8(8):e13625
Scale-up of hepatitis C treatment in prisons is key to national elimination.
Papaluca T, Hellard ME, Thompson AJV, Lloyd AR
Med J Aust. 2019 May; 210(9):391-393
"I'm obviously not dying so it's not something I need to sort out today": Considering hepatitis C treatment in the era of direct acting antivirals.
Wright C, Cogger S, Hsieh K, Goutzamanis S, Hellard M, Higgs P
Infect Dis Health. 2019 May; 24(2):58-66
Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
Traeger MW, Cornelisse VJ, Asselin J, Price B, Roth NJ, Willcox J, Tee BK, Fairley CK, Chang CC, Armishaw J, Vujovic O, Penn M, Cundill P, Forgan-Smith G, Gall J, Pickett C, Lal L, Mak A, Spelman TD, Nguyen L, Murphy DA, Ryan KE, El-Hayek C, West M, Ruth S, Batrouney C, Lockwood JT, Hoy JF, Hellard ME, Stoové MA, Wright EJ; PrEPX Study Team
JAMA. 2019 Apr; 321(14):1380-1390
Genomic variability of within-host hepatitis C variants in acute infection.
Rodrigo C, Leung P, Lloyd AR, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Eltahla AA; InC3 Collaborative
J Viral Hepat. 2019 Apr; 26(4):476-484
People who inject drugs in Bangladesh - the untold burden!
Khan SI, Reza MM, Crowe SM, Rahman M, Hellard M, Sarker MS, Chowdhury EI, Rana AM, Sacks-Davis R, Banu S, Ross AG
Int J Infect Dis. 2019 Mar; 83:109-115
Tracking the uptake of outcomes of hepatitis B virus testing using laboratory data in Victoria, 2011-2016; a population-level cohort study.
van Gemert C, Dimech W, Stoové M , Guy R , Howell J , Bowden S, Nicholson S , Pendle S , Donovan B , Hellard M
Sexual Health. 2019 Mar; 16:358-366
Injecting drug use is an independent risk factor for reincarceration after release from prison: A prospective cohort study.
Winter RJ, Stoové M, Agius PA, Hellard ME, Kinner SA
Drug Alcohol Rev. 2019 Mar; 38(3):254-263
Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs.
Latham NH, Pedrana A, Doyle JS, Howell J, Williams B, Higgs P, Thompson AJ, Hellard ME
J Viral Hepat. 2019 Feb; 26(7):919-922
Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004-2015.
McManus H, Callander D, Donovan B, Russell DB, O'Connor CC, Davies SC, Lewis DA, Hellard ME, Chen MY, Petoumenos K, Varma R, Cogle A, Boyd MA, Grulich A, Pollard J, Medland N, Fairley CK, Guy RJ
Med J Aust. 2019 Feb; 210(6):269-275
HIV diagnoses in migrant populations in Australia-A changing epidemiology.
Gunaratnam P, Heywood AE, McGregor S, Jamil MS, McManus H, Mao L, Lobo R, Brown G, Hellard M, Marukutira T, Bretaña NA, Lang C, Medland N, Bavinton B, Grulich A, Guy R
PLoS One. 2019 Feb; 14(2):e0212268
Estimating the syphilis epidemic among gay, bisexual and other men who have sex with men in Australia following changes in HIV care and prevention.
Wilkinson A, Scott N, Tidhar T, Luong P, El-Hayek C , Wilson D, Fairley C, Zhang L, Leslie D , Roth N , Tee BK , Hellard M , Stoové M
Sex Health. 2019 Feb; 16(3):254-262
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.
Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts TR, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ; Lancet Gastroenterology & Hepatology Commissioners.
Lancet Gastroenterol Hepatol. 2019 Feb; 4(2):135-184
A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015.
Bartlett SR, Applegate TL, Jacka BP, Martinello M, Lamoury FM, Danta M, Bradshaw D, Shaw D, Lloyd AR, Hellard M, Dore GJ, Matthews GV, Grebely J
J Int AIDS Soc. 2019 Feb; 22(2):e25222
Outcomes of treatment for hepatitis C in prisoners using a nurse-led, state-wide model of care.
Papaluca T, McDonald L, Craigie A, Gibson A, Desmond P, Wong D, Winter R, Scott N, Howell J, Doyle J, Pedrana A, Lloyd A, Stoové M, Hellard M, Iser D, Thompson A
J Hepatol. 2019 Jan; 70(5):839-846
Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.
Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).
Liver Int. 2019 Jan; 39(1):20-30
Aiming for the elimination of viral hepatitis in Australia, New Zealand, the Pacific Islands and Territories: where are we now and barriers to meeting WHO targets by 2030.
Howell J, Pedrana A, Cowie BC, Doyle J, Getehun A, Ward J, Gane E, Cunningham C, Wallace J, Lee A, Malani J, Thompson A, Hellard ME
J Gastroenterol Hepatol. 2019 Jan; 34(1):40-48
Improving hepatitis C direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived-experience.
Goutzamanis S, Doyle J, Higgs P, Hellard M
J Viral Hepat. 2019 Jan; 26(2):218-223
The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals.
Popping S, Bade D, Boucher C, van der Valk M, El-Sayed M, Sigurour O, Sypsa V, Morgan T, Gamkrelidze A, Mukabatsinda C, Deuffic-Burban S, Ninburg M, Feld J, Hellard M, Ward J
J Virus Erad. 2019 Jan; 5(1):60-66
Injection drug network characteristics as a predictor of injection behaviour.
Spelman T, Sacks-Davis R, Dietze P, Higgs P, Hellard M
Epidemiol Infect. 2019 Jan; 147:e173

2018 (44)

Monitoring the Control of Sexually Transmissible Infections and Blood-Borne Viruses: Protocol for the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS).
Callander D, Moreira C, El-Hayek C, Asselin J, van Gemert C, Watchirs Smith L, Nguyen L, Dimech W, Boyle DI, Donovan B, Stoové M, Hellard M, Guy R
JMIR Res Protoc. 2018 Nov; 7(11):e11028
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, Dalgard O, Lacombe K, Feld JJ, Bruneau J, Daulouede JP, Powis J, Bruggmann P, Matthews GV, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate TL, Crawford S, Dore GJ; D3FEAT Study Group
Int J Drug Policy. 2018 Oct; 62:94-103
Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.
Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, Trickey A, Abbott S, Strathdee SA, Abramovitz D, Maher L, Iversen J, Bruneau J, Zang G, Garfein RS, Yen YF, Azim T, Mehta SH, Milloy MJ, Hellard ME, Sacks-Davis R, Dietze PM, Aitken C, Aladashvili M, Tsertsvadze T, Mravčík V, Alary M, Roy E, Smyrnov P, Sazonova Y, Young AM, Havens JR, Hope VD, Desai M, Heinsbroek E, Hutchinson SJ, Palmateer NE, McAuley A, Platt L, Martin NK, Altice FL, Hickman M, Vickerman P
Lancet Infect Dis. 2018 Oct; 18(12):1397-1409
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study.
Cunningham EB, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, Hellard M, Cooper C, Read P, Conway B, Dunlop AJ, Norton B, Litwin AH, Hajarizadeh B, Thurnheer MC, Dillon JF, Weltman M, Shaw D, Bruggmann P, Gane E, Fraser C, Marks P, Applegate TL, Quiene S, Siriragavan S, Matthews GV, Dore GJ, Grebely J; SIMPLIFY study group
Int J Drug Policy. 2018 Oct; 62:14-23
Aiming for 90-90-90 - the importance of understanding the risk factors for HIV exposure and advanced HIV infection in migrant populations and other groups who do not report male-to-male sex.
Peach E, Lemoh C, Stoové M, Agius P, El Hayek C, Higgins N, Hellard M
Sex Health. 2018 Oct; 15(5):441-450
Blood-borne virus transmission in an urban, culturally diverse neighbourhood: results from a cross-sectional bio-behavioural survey using innovative outreach methods in a hard-to-reach population.
Peach E, Cogger S, Byron K, Francis P, O'Keefe D, Higgs P, Stoove M, Elmore K, Dietze P, Hellard M
Sex Health. 2018 Oct; 15(1):54-60
Pathways to ensure universal and affordable access to hepatitis C treatment.
Douglass CH, Pedrana A, Lazarus JV, 't Hoen EFM, Hammad R, Leite RB, Hill A, Hellard M
BMC Med. 2018 Oct; 16(1):175
Description of social contacts among student cases of pandemic influenza during the containment phase, Melbourne, Australia, 2009.
Caroline van Gemert, Emma S McBryde, Isabel Bergeri, Rachel Sacks-Davis, Hassan Vally, Tim Spelman, Brett Sutton, Margaret Hellard
Western Pac Surveill Response J. 2018 Oct; 9(5 Suppl 1):27-34
Achieving a hepatitis C cure: a qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia.
Richmond JA, Ellard J, Wallace J, Thorpe R, Higgs P, Hellard M, Thompson A
Hepatol Med Policy. 2018 Aug; 3:8
Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model.
Scott N, Ataide R, Wilson DP, Hellard M, Price RN, Simpson JA, Fowkes FJI
Malar J. 2018 Aug; 17(1):279
Evolutionary study and phylodynamic pattern of human influenza A/H3N2 virus in Indonesia from 2008 to 2010.
Agustiningsih A, Trimarsanto H, Restuadi R, Artika IM, Hellard M, Muljono DH
PLoS One. 2018 Aug; 13(8):e0201427
Safe sex in chick lit: a ‘novel’ analysis of sexual health references in popular women’s fiction.
Lim MSC, Hellard ME, Horyniak
Sex Health. 2018 Jul; 15(5):468-472
Eliminating hepatitis C: the importance of frequent testing of people who inject drugs in high prevalence settings.
Scott N, Sacks-Davis R, Pedrana A, Doyle J, Thompson A, Hellard M
J Viral Hepat. 2018 Jul; 25(12):1472-1480
Mobile Phone-Based Ecological Momentary Intervention to Reduce Young Adults' Alcohol Use in the Event: A Three-Armed Randomized Controlled Trial.
Wright C, Dietze PM, Agius PA, Kuntsche E, Livingston M, Black OC, Room R, Hellard M, Lim MS
JMIR Mhealth Uhealth. 2018 Jul; 6(7):e149
Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.
Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
Trials. 2018 Jul; 19(1):383
Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework.
Popping S, El-Sayed M, Feld J, Hatzakis A, Hellard M, Lesi O, Ninburg M, Ward J, Boucher C
J Virus Erad. 2018 Jul; 4(3):193-195
Hepatitis C virus notification rates in Australia are highest in socioeconomically disadvantaged areas.
Hainsworth SW, Dietze PM, Wilson DP, Sutton B, Hellard ME, Scott N
PLoS One. 2018 Jun; 13(6):e0198336
Measuring and understanding the attitudes of Australian gay and bisexual men towards biomedical HIV prevention using cross-sectional data and factor analyses.
Wilkinson AL, Draper BL, Pedrana AE, Asselin J, Holt M, Hellard ME, Stoové M
Sex Transm Infect. 2018 Jun; 94(4):309-3014
Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study.
Scott N, Palmer A, Morgan C, Lesi O, Spearman CW, Sonderup M, Hellard M
Lancet Glob Health. 2018 Jun; 6(6):e659-e667
Eliminating HIV/HCV co-infection in gay and bisexual men: is it achievable through scaling up treatment?
Sacks-Davis R, Pedrana AE, Scott N, Doyle JS, Hellard ME
Expert Rev Anti Infect Ther. 2018 May; 16(5):411-422
Implications of survey labels and categorisations for understanding drug use in the context of sex among gay and bisexual men in Melbourne, Australia.
Ryan KE, Wilkinson AL, Pedrana A, Quinn B, Dietze P, Hellard M, Stoové M
Int J Drug Policy. 2018 May; 55:183-186
Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C.
Wade AJ, McCormack A, Roder C, McDonald K, Davies M, Scott N, Wardrop M, Athan E, Hellard ME
J Viral Hepat. 2018 Apr; 25(9):1089-1098
Experiences of liver health related uncertainty and self-reported stress among people who inject drugs living with hepatitis C virus: a qualitative study.
Goutzamanis S, Doyle JS, Thompson A, Dietze P, Hellard M, Higgs P; TAP study group.
BMC Infect Dis. 2018 Apr; 18(1):151
Undiagnosed HIV infections among gay and bisexual men increasingly contribute to new infections in Australia.
Gray RT, Wilson DP, Guy RJ, Stoové M, Hellard ME, Prestage GP, Lea T, de Wit J, Holt M
J Int AIDS Soc. 2018 Apr; 21(4):e25104
Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.
Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME
J Int AIDS Soc. 2018 Apr; 21 Suppl 2:e25051
Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access.
Scott N, Hainsworth SW, Sacks-Davis R, Pedrana A, Doyle J, Wade A, Hellard M
J Virus Erad. 2018 Apr; 4(2):108-114
Achieving 90-90-90 HIV targets will not be enough to achieve the HIV incidence reduction target in Australia.
Scott N, Stoové M, Kelly SL, Wilson DP, Hellard ME
Clin Infect Dis. 2018 Mar; 66(7):1019-1023
Comparing Australian gay and bisexual men with undiagnosed and recently diagnosed HIV infection to those in the National HIV Registry.
Down I, Prestage G, Brown G, Ellard J, Guy R, Hellard M, Wilson D, de Wit J, Stoové M, Holt M
Sex Health. 2018 Mar; 15(3):276-281
Effects of Pre-exposure Prophylaxis for the Prevention of HIV Infection on Sexual Risk Behavior in Men Who Have Sex with Men: A Systematic Review and Meta-analysis.
Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS, Stoové MA
Clin Infect Dis. 2018 Mar; 67(5):676-686
Rising Chlamydia and Gonorrhoea Incidence and Associated Risk Factors Among Female Sex Workers in Australia: A Retrospective Cohort Study.
Callander D, McManus H, Guy R, Hellard M, O'Connor CC, Fairley CK, Chow EPF, McNulty A, Lewis DA, Carmody C, Schmidt HA, Kim J, Donovan B
Sex Transm Dis. 2018 Mar; 45(3):199-206
A tale of two countries: progress towards UNAIDS 90-90-90 targets in Botswana and Australia.
Marukutira T, Stoové M, Lockman S, Mills LA, Gaolathe T, Lebelonyane R, Jarvis JN, Kelly SL, Wilson DP, Luchters S, Crowe SM, Hellard M
J Int AIDS Soc. 2018 Mar; 21(3):e25090
Declining prevalence of undiagnosed HIV in Melbourne: results from community-based bio-behavioural studies of gay and bisexual men.
Stoové M, Asselin J, Pedrana A, Lea T, Hellard M, Wilson D, Prestage G, de Wit J, Holt M
Aust N Z J Public Health. 2018 Feb; 42(1):57-61
People Born In Non-Main English Speaking Countries Are Less Likely To Start Hiv Treatment Early In Australia: A National Cohort Analysis, 2014-15.
Gunaratnam P, McManus H, Watchirs-Smith L, McGregor S, Callander D, Brown G, Lobo R, O'Connor CC, Hellard M, Medland N, Lewis D, Palmer C, Law M, Gray R, Donovan B, Guy R; ACCESS Steering Committee
J Acquir Immune Defic Syndr. 2018 Feb; 77(3):e31-e34
Achieving hepatitis C elimination in Europe - to treatment scale up and beyond.
Hellard M, Scott N, Sacks Davis R, Pedrana A
J Hepatol. 2018 Feb; 68(3):383-385
Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020.
Scott N, Ólafsson S, Gottfreðsson M, Tyrfingsson T, Rúnarsdóttir V, Hansdottir I, Benitez Hernandez U, Sigmundsdóttir G, Hellard M
J Hepatol. 2018 Feb; 68(5):932-939
Drug Use in Prisoners and Hepatitis (Book Chapter)
Winter RJ, Hellard ME
"in ""Drug Use in Prisoners: Epidemiology, Implications, and Policy Responses"" Eds Stuart A, Kinner and Josiah D. Jody Rich ". 2018 Feb; Chapter 9
What Behaviors Do Young Heterosexual Australians See in Pornography? A Cross-Sectional Study.
Davis AC, Carrotte ER, Hellard ME, Lim MSC
J Sex Res. 2018 Jan; 55(3):310-319
The effect of female sex on hepatitis C incidence among people who inject drugs: results from the international multi-cohort InC3 Collaborative.
Esmaeili A, Mirzazadeh A, Morris MD, Hajarizadeh B, Sacks HS, Maher L, Grebely J, Kim AY, Lauer G, Cox AL, Hellard M, Dietze P, Bruneau J, Shoukry NH, Dore GJ, Lloyd AR, Prins M, Page K; InC3 Collaborative.
Clin Infect Dis. 2018 Jan; 66(1):20-28
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group
Lancet Gastroenterol Hepatol. 2018 Jan; 3(3):153-161
Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour.
Scott N, Stoové M, Wilson DP, Keiser O, El-Hayek C, Doyle J, Hellard M
J Int AIDS Soc. 2018 Jan; 21(1):e25059
Understanding the Targeting and Uptake of HIV Testing Among Gay and Bisexual Men Attending Sexual Health Clinics.
Jamil MS, McManus H, Callander D, Prestage G, Ali H, O'Connor CC, Chen M, McNulty AM, Knight V, Duck T, Keen P, Gray J, Medland N, Hellard M, Lewis DA, Grulich AE, Kaldor JM, Fairley CK, Donovan B, Guy RJ; ACCESS and NSW Partnership Project Steering Committees.
AIDS Behav. 2018 Jan; 22(2):513-521
Acceptability and HIV prevention benefits of a peer-based model of rapid point of care HIV testing for Australian gay, bisexual and other men who have sex with men.
Leitinger D, Ryan KE, Brown G, Pedrana A, Wilkinson AL, Ryan C, Hellard M, Stoové M
AIDS Behav. 2018 Jan; 22(1):178-189
Syndromic management of sexually transmissible infections in resource-poor settings: a systematic review with meta-analysis of the abnormal vaginal discharge flowchart for Neisseria gonorrhoea and Chlamydia trachomatis.
van Gemert C, Hellard M, Bradshaw CS, Fowkes FJI, Agius PA, Stoove M, Bennett CM
Sex Health. 2018 Jan; 15(1):1-12
Epidemiology of chronic hepatitis B virus in Ireland using routinely collected surveillance and administrative data, 2004-2014.
van Gemert CE, Murphy N, Mitchell TA, Hellard ME, Thornton L
Ir J Med Sci. 2018 Jan; 187(3):803-811

2017 (34)

Hepatitis C testing and re-testing among people attending sexual health services in Australia, and hepatitis C incidence among people with human immunodeficiency virus: analysis of national sentinel surveillance data.
Boettiger DC, Law MG, Dore GJ, Guy R, Callander D, Donovan B, O'Connor CC, Fairley CK, Hellard M, Matthews G
BMC Infect Dis. 2017 Dec; 17(1):740
WHO guidelines on testing for hepatitis B and C - meeting targets for testing.
Hellard ME, Chou R, Easterbrook P
BMC Infect Dis. 2017 Nov; 17(Suppl 1):703
Methodological challenges in appraising evidence on diagnostic testing for WHO guidelines on hepatitis B and hepatitis C virus infection.
Chou R, Easterbrook P, Hellard M
BMC Infect Dis. 2017 Nov; 17(Suppl 1):694
Trial and error: evaluating and refining a community model of HIV testing in Australia.
Ryan KE, Pedrana A, Leitinger D, Wilkinson AL, Locke P, Hellard ME, Stoové M
BMC Health Serv Res. 2017 Oct; 17(1):692
Pathways to the elimination of hepatitis C: prioritising access for all.
Pedrana AE, Sacks-Davis R, Doyle JS, Hellard ME
Expert Rev Clin Pharmacol. 2017 Oct; 10(10):1023-1026
Anorectal swabs as a marker of male-to-male sexual exposure in STI surveillance systems.
Ampt FH, El Hayek C, Agius PA, Bowring AL, Bartnik N, Van Gemert C, Fairley CK, Chow EPF, Bradshaw CS, Stephens N, Lim MSC, Hellard ME
Epidemiol Infect. 2017 Sep; 145(12):2530-2535
Knowledge and practices of chronic hepatitis B virus testing by general practitioners in Victoria, Australia, 2014-15.
van Gemert C, Howell J, Wang J, Stoové M, Cowie B, Allard N, Enright C, Dunn E, Towell V, Hellard M
Aust Fam Physician. 2017 Sep; 46(9):683-689
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ; ACTIVATE Study Group.
Int J Drug Policy. 2017 Sep; 47:177-186
Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME
Int J Drug Policy. 2017 Sep; 47:107-116
WHISPER or SHOUT study: protocol of a cluster-randomised controlled trial assessing mHealth sexual reproductive health and nutrition interventions among female sex workers in Mombasa, Kenya.
Ampt FH, Mudogo C, Gichangi P, Lim MSC, Manguro G, Chersich M, Jaoko W, Temmerman M, Laini M, Comrie-Thomson L, Stoové M, Agius PA, Hellard M, L'Engle K, Luchters S
BMJ Open. 2017 Aug; 7(8):e017388
Young Australians' use of pornography and associations with sexual risk behaviours.
Lim MSC, Agius PA, Carrotte ER, Vella AM, Hellard ME
Aust N Z J Public Health. 2017 Aug; 41(4):438-443
Increased syphilis testing of men who have sex with men: greater detection of asymptomatic early syphilis and relative reduction in secondary syphilis.
Chow EPF, Callander D, Fairley CK, Zhang L, Donovan B, Guy R, Lewis DA, Hellard M, Read P, Ward A, Chen MY; ACCESS collaboration.
Clin Infect Dis. 2017 Aug; 65(3):389-395
New hepatitis C antiviral treatments eliminate the virus.
Doyle JS, Thompson AJ, Higgs P, Stoove M, Dietze PM, Hellard ME
Lancet. 2017 Jul; 390(10092):358-359
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.
Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L, Midgard H, Larney S, Degenhardt L, Alho H, Byrne J, Dillon JF, Feld JJ, Foster G, Goldberg D, Lloyd AR, Reimer J, Robaeys G, Torrens M, Wright N, Maremmani I, Norton BL, Litwin AH, Dore GJ; International Network on Hepatitis in Substance Users.
Int J Drug Policy. 2017 Jul; 47:51-60
Re-examining blood donor deferral criteria relating to injecting drug use.
Quinn B, Seed C, Keller A, Maher L, Wilson D, Farrell M, Caris S, Williams J, Madden A, Thompson A, Pink J, Hellard ME
Int J Drug Policy. 2017 Jun; 48:9-17
Injecting drug use in low and middle income countries: opportunities to improve care and prevent harm.
O'Keefe D, Stoové M, Doyle J, Dietze P, Hellard M.
J Viral Hepat. 2017 Jun; 24(9):714-724
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J; ACTIVATE Study Group.
Int J Drug Policy. 2017 Jun; 47:230-238
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J; ACTIVATE Study Group
BMC Infect Dis. 2017 Jun; 17(1):420
A cross-sectional study of HIV and STIs among male sex workers attending Australian sexual health clinics.
Callander D, Read P, Prestage G, Minichiello V, Chow EP, Lewis DA, McNulty A, Ali H, Hellard M, Guy R, Donovan B
Sex Transm Infect. 2017 Jun; 93(4):299-302
An ecological momentary intervention to reduce alcohol consumption in young adults delivered during drinking events: Protocol for a pilot randomized controlled trial.
Wright CJ, Dietze PM, Agius PA, Kuntsche E, Room R, Livingston M, Hellard M, Lim MS
JIMR Research Protocols. 2017 May; 6(5):e95
"We Might Get Some Free Beers": Experience and Motivation for Transactional Sex Among Behaviorally Bisexual Men in Vientiane, Laos.
Bowring AL, Pasomsouk N, Hughes C, van Gemert C, Higgs P, Sychareun V, Hellard M, Power R
Arch Sex Behav. 2017 May; 46(4):1047-1059
Correlates of sexually transmissible infection testing among a sample of at-risk young Australians.
Douglass CH, Vella AM, Hellard ME, Lim MSC
Aust J Prim Health. 2017 Apr; 23(3):272-277
Wilkinson et al. Respond to "Latent Transition Analyses in Clinical Cohorts".
Wilkinson AL, El-Hayek C, Fairley CK, Roth N, Tee BK, McBryde E, Hellard M, Stoové M
Am J Epidemiol. 2017 Apr; 185(8):639-640
Utility of risk-based chlamydia testing in primary care: analysis of retrospective surveillance data among women in Melbourne, Australia.
Wilkinson AL, McNamee K, El-Hayek C, Chow EP, Bradshaw CS, Roth N, Tee BK, Stoové M, Hellard M
Sex Health. 2017 Apr; 14(3):268-273
Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 Collaboration.
Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, Prins M, Cox AL, Dore G, Grebely J, Kim AY, Lauer GM, Lloyd A, Rice T, Shoukry N, Maher L, Page K; International Collaboration of Incident HIV and HCV in Injecting Cohorts (InC3).
Clin Infect Dis. 2017 Apr; 64(7):860-869
A survey of hepatitis C management by Victorian GPs after PBS-listing of direct-acting antiviral therapy.
Wade A, Draper B, Doyle J, Allard N, Grinzi P, Thompson A, Hellard M
Aust Fam Physician. 2017 Apr; 46(4):235-240
Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
Scott N, McBryde ES, Thompson A, Doyle JS, Hellard ME
Gut. 2017 Mar; 66(8):1507-1515
Measuring transitions in sexual risk among Men Who Have Sex With Men: The novel use of latent class and latent transition analysis in HIV sentinel surveillance.
Wilkinson AL, El-Hayek C, Fairley CK, Roth N, Tee BK, McBryde E, Hellard M, Stoové M
Am J Epidemiol. 2017 Mar; 185(8):627-635
Targeted direct-acting antiviral treatment for chronic hepatitis C: a financial reality or an obstacle to elimination?
Hellard M, Pedrana A, Scott N
J Hepatol. 2017 Feb; 66(2):270-272
HCV reinfection incidence among individuals treated for recent infection.
Martinello M, Grebely J, Petoumenos K, Gane E, Hellard M, Shaw D, Sasadeusz J, Applegate TL, Dore GJ, Matthews GV
J Viral Hepat. 2017 Feb; 24(5):359-370
Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.
Rodrigo C, Walker MR, Leung P, Eltahla AA, Grebely J, Dore GJ, Applegate T, Page K, Dwivedi S, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Luciani F, Lloyd AR, Bull RA; InC3 Study Group
Infect Genet Evol. 2017 Jan; 49:88-96
Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
Eltahla AA, Rodrigo C, Betz-Stablein B, Grebely J, Applegate T, Luciani F, Schinkel J, Dore GJ, Page K, Bruneau J, Morris MD, Cox AL, Kim AY, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Lloyd AR, Bull RA; InC3 Study Group.
J Viral Hepat. 2017 Jan; 24(1):37-42
Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.
Rodrigo C, Eltahla AA, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Lloyd AR; InC3 Collaborative
J Viral Hepat. 2017 Jan; 24(1):43-52
A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies.
Bartlett SR, Wertheim JO, Bull RA, Matthews GV, Lamoury FM, Scheffler K, Hellard M, Maher L, Dore GJ, Lloyd AR, Applegate TL, Grebely J
J Viral Hepat. 2017 Jan; 24(5):404-411

2016 (37)

Achieving development goals for HIV, tuberculosis and malaria in sub-Saharan Africa through integrated antenatal care: barriers and challenges.
Fowkes FJ, Draper BL, Hellard M, Stoové M
BMC Med. 2016 Dec; 14(1):202
A longitudinal cohort study of HIV 'treatment as prevention' in gay, bisexual and other men who have sex with men: the Treatment with Antiretrovirals and their Impact on Positive And Negative men (TAIPAN) study protocol.
Callander D, Stoové M, Carr A, Hoy JF, Petoumenos K, Hellard M, Elliot J, Templeton DJ, Liaw S, Wilson DP, Grulich A, Cooper DA, Pedrana A, Donovan B, McMahon J, Prestage G, Holt M, Fairley CK, McKellar-Stewart N, Ruth S, Asselin J, Keen P, Cooper C, Allan B, Kaldor JM, Guy R
BMC Infect Dis. 2016 Dec; 16(1):752
The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males.
Tsui JI, Mirzazadeh A, Hahn JA, Maher L, Bruneau J, Grebely J, Hellard M, Kim AY, Shoukry NH, Cox AL, Prins M, Dore GJ, Lauer G, Lloyd AR, Page K
Drug Alcohol Depend. 2016 Dec; 169:156-62
Direct-acting antiviral treatment for HCV.
Goutzamanis S, Doyle J, Thompson A, Hellard M, Higgs P
Lancet Infect Dis. 2016 Dec; 16(12):1325-6
Sofosbuvir and ribavirin for six weeks is not effective among people with recent HCV infection: The DARE-C II study.
Martinello M, Gane E, Hellard M, Sasadeusz J, Shaw D, Petoumenos K, Applegate T, Grebely J, Maire L, Marks P, Dore GJ, Matthews GV
Hepatology. 2016 Dec; 64(6):1911-1921
Lack of heterologous cross-reactivity towards HLA-A*02:01 restricted viral epitopes is underpinned by distinct alphabetaT cell receptor signatures.
Grant EJ, Josephs TM, Valkenburg SA, Wooldridge L, Hellard M, Rossjohn J, Bharadwaj M, Kedzierska K, Gras S
J Biol Chem. 2016 Nov; 291(47):24335-24351
Historical trends in the hepatitis C virus epidemics in North America and Australia.
Rodrigo C, Eltahla AA, Bull RA, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Estes C, Razavi H, Lloyd AR, Luciani F; InC3 Study Group
J Infect Dis. 2016 Nov; 214(9):1383-1389
A nurse-led intervention improved blood-borne virus testing and vaccination in Victorian prisons.
Winter RJ, White B, Kinner SA, Stoové M, Guy R, Hellard ME
Aust N Z J Public Health. 2016 Oct; 40(6):592-594
Exploring attitudes towards sexting of young people: a cross-sectional study.
Lim MS, Vella AM, Horyniak DR, Hellard ME
Sexual Health. 2016 Oct; 13(6):530-535
Resumption of injecting drug use following release from prison in Australia.
Winter RJ, Young JT, Stoové M, Agius PA, Hellard ME, Kinner SA
Drug Alcohol Depend. 2016 Sep; 168:104-111
Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men.
Bradshaw D, Raghwani J, Jacka B, Sacks-Davis R, Lamoury F, Down I, Prestage G, Applegate TL, Hellard M, Sasadeusz J, Dore GJ, Pybus OG, Matthews GV, Danta M
PLoS One. 2016 Sep; 11(9):e0162002
A 'test and treat' prevention strategy in Australia requires innovative HIV testing models: a cohort study of repeat testing among 'high-risk' men who have sex with men.
Wilkinson AL, El-Hayek C, Spelman T, Fairley CK, Leslie D, McBryde ES, Hellard M, Stoové M
Sex Transm Infect. 2016 Sep; 92(6):464-466
Characteristics of gay, bisexual and other men who have sex with men testing and retesting at Australia’s first shop-front rapid point-of-care HIV testing service.
Ryan KE, Wilkinson AL, Leitinger D, El-Hayek C, Ryan C, Pedrana A, Hellard M, Stoové M
Sex Health. 2016 Aug; 13(6):560-567
"I am yet to encounter any survey that actually reflects my life": a qualitative study of inclusivity in sexual health research.
Carrotte ER, Vella AM, Bowring AL, Douglass C, Hellard ME, Lim MS
BMC Med Res Methodol. 2016 Jul; 16(1):86
Field engagement further facilitates hepatitis B vaccination completion: Letter in response to: Day et al. (in press).
Higgs P, Doyle J, Luppi J, Dietze P, Hellard M
J Clin Virol. 2016 Jul; 82:64-65
Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees.
Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, Courtney R, McKee M, Amon JJ, Maher L, Hellard M, Beyrer C, Altice FL
Lancet. 2016 Jul; 388(10049):1089-1102
Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.
Doyle JS, Grebely J, Spelman T, Alavi M, Matthews GV, Thompson AJ, Dore GJ, Hellard ME; ATAHC Study Group.
PLoS One. 2016 Jun; 11(6):e0150655
Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks.
Hellard M, Sacks-Davis R, Doyle J
J Epidemiol Commun Health. 2016 Jun; 70:1151-1154
Water, Sanitation, and Hygiene Facilities and Hygiene Practices Associated with Diarrhea and Vomiting in Monastic Schools, Myanmar.
Weaver ER, Agius PA, Veale H, Dorning K, Hlang TT, Aung PP, Fowkes FJ, Hellard ME
Am J Trop Med Hyg. 2016 Jun; 95(2):278-287
Toll-like receptor expression and signalling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis C infection.
Chen Yi Mei SL, Burchell J, Skinner N, Millen R, Matthews G, Hellard M, Dore GJ, Desmond P, Sundararajan V, Thompson A, Visvanathan K, Sasadeusz J.
J Infect Dis. 2016 Jun; 214(5):739-747
HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection.
Lamoury FM, Hajarizadeh B, Keoshkerian E, Feld JJ, Amin J, Teutsch S, Matthews GV, Hellard M, Dore GJ, Lloyd AR, Applegate TL, Grebely J and the ATAHC Study Group.
BMC Infect Dis. 2016 Jun; 16(1):241
The role of living context in prescription opioid injection and the associated risk of hepatitis C infection.
Sacks-Davis R, Daniel M, Roy E, Kestens Y, Zang G, Ramos Y, Hellard M, Jutras Aswad D, Bruneau J
Addiction. 2016 May; 111(11):1985-1996
The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P
PLoS One. 2016 May; 11(5):e0156213
A systematic review of community based hepatitis C treatment.
Wade AJ, Veronese V, Hellard ME, Doyle JS.
BMC Infect Dis. 2016 May; 16(1):202
Letter: new treatments for hepatitis C have implications for quality of life in people who inject drugs.
Higgs P, Wright C, Hellard M
Aliment Pharmacol Ther. 2016 Apr; 43(7):840-841
Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection.
Hajarizadeh B, Lamoury FM, Feld JJ, Amin J, Keoshkerian E, Matthews GV, Hellard M, Dore GJ, Lloyd AR, Grebely J, Applegate TL; ATAHC Study Group.
Virol J. 2016 Feb; 13(1):32
Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.
Martinello M, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, Yeung B, Maire L, Iser D, Lloyd A, Thompson A, Sasadeusz J, Haber P, Dore GJ, Matthews GV
Antivir Ther. 2016 Feb; 21(5):425-434
Improving the identification of priority populations to increase hepatitis B testing rates, 2012.
van Gemert C, Wang J, Simmons J, Cowie B, Boyle D, Stoove M, Enright C, Hellard M
BMC Public Health. 2016 Feb; 16(1):95
Modelling hepatitis C virus transmission among people who inject drugs: assumptions, limitations and future challenges.
Scott N, Hellard M, McBryde E
Virulence. 2016 Feb; 7(2):201-208
Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
Scott N, Iser D, Thompson A, Doyle J, Hellard M
J Gastroenterol Hepatol. 2016 Feb; 31(4):872-882
The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand.
Howell J, Balderson G, Hellard M, Gow PJ, Strasser SI, Stuart KA, Wigg A, Jeffrey G, Gane E, Angus PW
J Gastroenterol Hepatol. 2016 Feb; 31(2):434-441
HIV and Sexual Risk Among Men Who Have Sex With Men and Women in Asia: A Systematic Review and Meta-Analysis.
Bowring AL, Veronese V, Doyle JS, Stoové M, Hellard M
AIDS Behav. 2016 Jan; 20(10):2243-2265
Mental Health and Associated Sexual Health Behaviours in a Sample of Young People Attending a Music Festival in Melbourne, Victoria.
Carrotte ER, Vella AM, Hellard ME, Lim MS
Community Ment Health J. 2016 Jan; 52(8):1082-1088
The impact of pornography on gender-based violence, sexual health and well-being: what do we know?
Lim MS, Carrotte ER, Hellard ME
J Epidemiol Community Health. 2016 Jan; 70(1):3-5
Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative.
Page K, Mirzazadeh A, Rice TM, Grebely J, Kim AY, Cox AL, Morris MD, Hellard M, Bruneau J, Shoukry NH, Dore GJ, Maher L, Lloyd AR, Lauer G, Prins M, McGovern BH
Open Forum Infect Dis. 2016 Jan; 3(1):ofw024
HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.
Bartlett SR, Jacka B, Bull RA, Luciani F, Matthews GV, Lamoury FM, Hellard ME, Hajarizadeh B, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T
Infect Genet Evol. 2016 Jan; 37:252-258
The Impact of a Social Marketing Campaign on HIV and Sexually Transmissible Infection Testing Among Men Who Have Sex With Men in Australia.
Wilkinson AL, Pedrana AE, El-Hayek C, Vella AM, Asselin J, Batrouney C, Fairley CK, Read TR, Hellard M, Stoové M
Sex Transm Dis. 2016 Jan; 43(1):49-56

2015 (31)

Sex and Sport: An Australian Rules Football-Based Chlamydia Screening Initiative (Book Chapter)
Kong FYS, Hellard M, Hocking J
in "Sport-Based Health Interventions" Ed David Conrad and Helen White (Springer). 2015 Dec; Chapter 11:151-159
The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service.
Wade AJ, Macdonald DM, Doyle JS, Gordon A, Roberts SK, Thompson AJ, Hellard ME
PLoS One. 2015 Nov; 10(11):e0142770
The prevalence and correlates of undiagnosed HIV among Australian gay and bisexual men: results of a national, community-based, bio-behavioural survey.
Holt M, Lea T, Asselin J, Hellard M, Prestage G, Wilson D, de Wit J, Stoové M
J Int AIDS Soc. 2015 Nov; 18(1):20526
Behavioural research to inform understanding of hepatitis C resistance.
Higgs P, Dwyer R, Cogger S, Hellard M, Maher L
Lancet Infect Dis. 2015 Nov; 15(11):1260-1261
Factors Influencing Access to Sexual Health Care Among Behaviorally Bisexual Men in Vientiane, Laos: A Qualitative Exploration.
Bowring AL, Pasomsouk N, Higgs P, Sychareun V, Hellard M, Power R
Asia Pac J Public Health. 2015 Nov; 27(8):820-834
Vaccination Programs for Endemic Infections: Modelling Real versus Apparent Impacts of Vaccine and Infection Characteristics.
Ragonnet R, Trauer JM, Denholm JT, Geard NL, Hellard M, McBryde ES
Sci Rep. 2015 Oct; 5:15468
The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.
Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, Hellard M
BMC Med. 2015 Aug; 13:198
Recommendations for the management of hepatitis C virus infection among people who inject drugs.
Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; International Network for Hepatitis in Substance Users.
Int J Drug Policy. 2015 Jul; 26(10):1028-1038
It goes both ways: a cross-sectional study of buying and selling sex among young behaviourally bisexual men in Vientiane, Laos.
Bowring AL, van Gemert C, Vongsaiya K, Hughes C, Sihavong A, Phimphachanh C, Chanlivong N, Toole M, Hellard M.
Sex Health. 2015 Jul; 12(5):405-10
Overview of viral hepatitis treatment research in China. (WHO Report)
El-Hayek C, Zou H, Hua B, Cheah S, Majumdar S, Hellard M
WHO China. 2015 Jul
Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.
Doyle JS, Deterding K, Grebely J, Wedemeyer H, Sacks-Davis R, Spelman T, Matthews G, Rice TM, Morris MD, McGovern BH, Kim AY, Bruneau J, Lloyd AR, Page K, Manns MP, Hellard ME, Dore GJ and the InC3 Study Group.
J Viral Hepat. 2015 Jun; 22(12):1020-1023
Incidence and predictors of non-fatal drug overdose after release from prison among people who inject drugs in Queensland, Australia.
Winter RJ, Stoové M, Degenhardt L, Hellard ME, Spelman T, Jenkinson R, McCarthy DR, Kinner SA
Drug Alcohol Depend. 2015 Jun; 153:43-49
The changing landscape of hepatitis C treatment-not 'can we cure?' but 'who should we cure first?' Is this an ethical approach?
Hellard M, Scott N
Addiction. 2015 Jun; 110(6):984-985
Global policy and access to new hepatitis C therapies for people who inject drugs
Doyle JS, Aspinall EJ, Hutchinson SJ, Quinn B, Gore C, Wiktor SZ, Hellard ME
Int J Drug Policy. 2015 Jun; 26(11):1064-1071
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
Alavi M, Spelman T, Matthews GV, Haber PS, Day C, van Beek I, Walsh N, Yeung B, Bruneau J, Petoumenos K, Dolan K, Kaldor JM, Dore GJ, Hellard M, Grebely J; ATAHC Study Group
Int J Drug Policy. 2015 May; 26(10):976-983
Hepatitis C transmission and treatment as prevention - The role of the injecting network.
Hellard M, McBryde E, Sacks Davis R, Rolls DA, Higgs P, Aitken C, Thompson A, Doyle J, Pattison P, Robins G
Int J Drug Policy. 2015 May; 26(10):958-962
How "Hidden" Are Unobserved Networks Among People Who Inject Drugs?
Higgs P, Sacks-Davis R, Aitken C, Hellard M
Am J Public Health. 2015 Apr; 105(6):e3
Hepatitis C virus reinfection and spontaneous clearance of reinfection - the InC3 study.
Sacks-Davis R, Grebely J, Dore GJ, Osburn W, Cox AL, Rice TM, Spelman T, Bruneau J, Prins M, Kim AY, McGovern BH, Shoukry NH, Schinkel J, Allen TM, Morris M, Hajarizadeh B, Maher L, Lloyd AR, Page K, Hellard M; InC3 study group
J Infect Dis. 2015 Apr; 212(9):1407-19
Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study.
Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Dore GJ, Grebely J; InC3 Study Group
PLoS One. 2015 Apr; 10(4):e0122232
"Seek, Test, Treat" Lessons from Australia: A Study of HIV testing patterns from a cohort of men who have sex with men.
Wilkinson AL, El-Hayek C, Spelman T, Fairley C, Leslie D, McBryde E, Hellard M, Stoové M
J Acquir Immune Defic Syndr. 2015 Mar; 69(4):460-465
A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs.
Spelman T, Morris MD, Zang G, Rice T, Page K, Maher L, Lloyd A, Grebely J, Dore GJ, Kim AY, Shoukry NH, Hellard M, Bruneau J; International Collaborative of Incident HIV and Hepatitis C in Injecting Cohorts (InC3 Study).
J Epidemiol Community Health. 2015 Mar; 69(8):745-752
Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data.
Sacks-Davis R, McBryde E, Grebely J, Hellard M, Vickerman P
J R Soc Interface. 2015 Mar; 12(104)
Increased testing for Neisseria gonorrhoeae with duplex nucleic acid amplification tests in Australia: implications for surveillance.
Donovan B, Dimech W, Ali H, Guy R, Hellard M
Sex Health. 2015 Feb; 12(1):48-50
The use of social networking platforms for sexual health promotion: identifying key strategies for successful user engagement.
Veale HJ, Sacks-Davis R, Weaver ERN, Pedrana AE, Stoové MA, Hellard ME
BMC Public Health. 2015 Feb; 15(1):85
Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis.
Aspinall EJ, Doyle JS, Corson S, Hellard ME, Hunt D, Goldberg D, Nguyen T, Falck-Ytter Y, Morgan RL, Smith B, Stoové M, Wiktor SZ, Hutchinson S
Eur J Epidemiol. 2015 Feb; 30(2):115-129
Sexual identity, same-sex partners and risk behaviour among a community-based sample of young people in Australia.
Bowring AL, Vella AM, Degenhardt L, Hellard M, Lim MS
Int J Drug Policy. 2015 Feb; 26(2):153-161
Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC study.
Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; the InC3 Study Group.
J Viral Hepat. 2015 Jan; 22(9):708-717
'Ice epidemic'? Trends in methamphetamine use from three Victorian surveillance systems.
Lim MS, Cogger S, Quinn B, Hellard ME, Dietze PM
Aust N Z J Public Health. 2015 Jan; 39(2):194-195
Young people's comparative recognition and recall of an Australian Government Sexual Health Campaign.
Lim MS, Gold J, Bowring AL, Pedrana AE, Hellard ME
Int J STD AIDS. 2015 Jan; 26(6):398-401
Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.
Applegate TL, Gaudieri S, Plauzolles A, Chopra A, Grebely J, Lucas M, Hellard M, Luciani F, Dore GJ, Matthews GV
Antivir Ther. 2015 Jan; 20(2):199-208
A reality check for aspirational targets to end HIV.
Wilson DP, Stoové MA, Hellard M
Lancet HIV. 2015 Jan; 2(1):e11

2014 (30)

Young risk takers: Alcohol, illicit drugs, and sexual practices among a sample of music festival attendees.
Jenkinson R, Bowring A, Dietze P, Hellard M, Lim MSC
J Sex Trans Dis. 2014 Dec; 2014:e357239
Setting the scene: locations for meeting sex partners among behaviorally bisexual men in vientiane, laos, and opportunities for health promotion.
Bowring AL, van Gemert C, Vongsaiya K, Hughes C, Sihavong A, Phimphachanh C, Chanlivong N, Agius PA, Toole M, Hellard M
AIDS Educ Prev. 2014 Dec; 26(6):538-553
The medium and the message: fitting sound health promotion methodology into 160 characters.
Lim MS, Wright C, Hellard ME
JMIR Mhealth Uhealth. 2014 Nov; 2(4):e40
An extensive antigenic footprint underpins immunodominant TCR adaptability against a hypervariable viral determinant.
Nivarthi UK, Gras S, Kjer-Nielsen L, Berry R, Lucet IS, Miles JJ, Tracy SL, Purcell AW, Bowden DS, Hellard M, Rossjohn J, McCluskey J, Bharadwaj M
J Immunol. 2014 Oct; 193(11):5402-5413
Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC Study.
Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; InC(3)Study Group.
J Clin Virol. 2014 Sep; 61(3):430-434
Early age at first sex: associations with sexual health and sociodemographic factors among a sample of young music festival attendees in Melbourne.
Vella AM, Agius PA, Bowring AL, Hellard ME, Lim MS
Sex Health. 2014 Aug; 11(4):359-365
The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs.
Hellard M, Rolls DA, Sacks-Davis R, Robins G, Pattison P, Higgs P, Aitken C, McBryde E
Hepatology. 2014 Aug; 60(6):1861-1870
A Comparison of Risk Factors for Hepatitis C Among Young and Older Adult Prisoners.
van Dooren K, Kinner SA, Hellard M
J Correct Health Care. 2014 Aug; 20(4):280-291
Assessing the feasibility of hepatitis C virus vaccine trials: Results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study.
White B, Madden A, Prins M, Hellard M, Wand H, Dore GJ, Page K, Maher L
Vaccine. 2014 Aug; 32(42):5460-5467
An overview of hepatitis B prevalence, prevention and management in the pacific islands and territories.
Howell J, Van Gemert C, Lemoine M, Thursz M, Hellard M
J Gastroent Hepatol. 2014 Aug; 29(11):1854-1866
Effects of HIV antiretroviral therapy on sexual and injecting risk-taking behaviour: a systematic review and meta-analysis.
Doyle JS, Degenhardt L, Pedrana AE, McBryde ES, Guy R, Stoové MA, Weaver E, Grulich AE, Lo YR, Hellard M
Clin Infect Dis. 2014 Aug; 59(10):1483-1494
Reattendance and chlamydia retesting rates at 12 months among young people attending Australian general practice clinics 2007-10: a longitudinal study.
Weaver ER, Bowring AL, Guy R, van Gemert C, Hocking JS, Boyle DI, Merritt T, Heal C, Lau PM, Donovan B, Hellard ME
Sex Health. 2014 Jul; 11(4):366-369
Dynamics of HCV RNA levels during acute hepatitis C virus infection.
Hajarizadeh B, Grebely J, Applegate T, Matthews GV, Amin J, Petoumenos K, Hellard M, Rawlinson W, Lloyd A, Kaldor J, Dore GJ (on behalf of the ATAHC study group)
J Med Virol. 2014 Jul; 86(10):1722-1729
Prevalence, correlates, and attitudes towards sexting among young people in Melbourne, Australia
Yeung T, Horyniak D, Vella A, Hellard M, Lim M
Sex Healtrh. 2014 Jul; 11(4):332-339
Chlamydia among Australian Aboriginal and/or Torres Strait Islander people attending sexual health services, general practices and Aboriginal community controlled health services.
Ward J, Goller J, Ali H, Bowring A, Couzos S, Saunders M, Yau P, Kaldor JM, Hellard M, Guy RJ, Donovan B
BMC Health Serv Res. 2014 Jul; 14(1):285
A systematic review of immediate HCV RNA testing following HCV Antibody compared with HCV RNA testing at time of assessment for HCV therapy.
Hall K, Sacks-Davis R, Doyle J, Aspinall E, Hutchinson S, Hellard M
Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2014 Jul
Analysis of laboratory testing results collected in an enhanced chlamydia surveillance system in Australia, 2008-2010.
Dimech W, Lim MS, Van Gemert C, Guy R, Boyle D, Donovan B, Hellard M
BMC Infect Dis. 2014 Jun; 14(1):325
High chlamydia positivity rates in Indigenous people attending Australian sexual health services.
O'Connor CC, Ali H, Guy RJ, Templeton DJ, Fairley CK, Chen MY, Dickson BM, Marshall LJ, Grulich AE, Hellard ME, Kaldor JM, Donovan B, Ward JS
Med J Aust. 2014 Jun; 200(10):595-598
Moving towards HIV treatment as prevention.
Stoové MA, Pedrana AE, Hellard ME
Microbiol Aust. 2014 May; 35(2):88-90
No Drama: Key Elements to the Success of an HIV/STI-Prevention Mass-Media Campaign.
Pedrana AE, Hellard ME, Higgs P, Asselin J, Batrouney C, Stoové M
Qual Health Res. 2014 Apr; 24(5):695-705
Urbanisation and sexual health: Understanding bisexually active men in Hanoi, Vietnam.
Higgs P, Reddel S, Pham HV, Khoat VD, Hellard M
Health Psychol Behav Med. 2014 Apr; 2(1):613-622
Identifying risk: a comparison of risk between heterosexual-identifying bisexual men and other bisexual men in vientiane, laos.
Bowring A, van Gemert C, Vongsaiya K, Hughes C, Sihavong A, Phimphachanh C, Chanlivong N, Toole M, Hellard M
AIDS Educ Prev. 2014 Apr; 26(2):109-121
Young people's comfort receiving sexual health information via social media and other sources.
Lim MS, Vella A, Sacks-Davis R, Hellard ME
Int J STD AIDS. 2014 Mar; 25(14):1003-1008
Trends in chlamydia positivity among heterosexual patients from the Victorian Primary Care Network for Sentinel Surveillance, 2007-2011.
Lim MS, El-Hayek C, Goller JL, Fairley CK, Nguyen PL, Hamilton RA, Henning DJ, McNamee KM, Hellard ME, Stoove MA
Med J Aust. 2014 Feb; 200(3):166-169
Eradication of hepatitis C infection: The importance of targeting people who inject drugs.
Hellard M, Doyle JS, Sacks-Davis R, Thompson AJ, McBryde E
Hepatology. 2014 Jan; 59(2):366-369
Interferon-free hepatitis C treatment: one pill to fit all?
Hellard ME, Doyle J
Lancet. 2014 Jan; 383(9916):491-492
Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study.
Aspinall EJ, Weir A, Sacks-Davis R, Spelman T, Grebely J, Higgs P, Hutchinson SJ, Hellard ME
Int J Drug Policy. 2014 Jan; 25(1):179-182
Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis.
Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, Palmateer N, Doyle JS, Hellard ME, Hutchinson SJ
Int J Epidemiol. 2014 Jan; 43(1):235-248
Detection of HCV-Specific IFN-gamma Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users.
Flynn JK, Sacks-Davis R, Higgs P, Aitken C, Moneer S, Suppiah V, Tracy L, Ffrench R, Bowden S, Drummer H, George J, Bharadwaj M, Hellard M
Hepat Mon. 2014 Jan; 14(1):e14678
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C Virus infection.
Grebely J, Page K, Sacks-Davis R, Schim van der Loeff M, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, McGovern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M; the InC3 Study Group
Hepatology. 2014 Jan; 59(1):109-20

2013 (34)

Acquisition of HIV by African-Born Residents of Victoria, Australia: Insights from Molecular Epidemiology.
Lemoh C, Ryan CE, Sekawi Z, Hearps AC, Aleksic E, Chibo D, Grierson J, Baho S, Street A, Hellard M, Biggs BA, Crowe SM
PLoS One. 2013 Dec; 8(12):e84008
Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study.
Grebely J, Morris MD, Rice TM, Bruneau J, Cox AL, Kim AY, McGovern BH, Shoukry NH, Lauer G, Maher L, Lloyd AR, Hellard M, Prins M, Dore GJ, Page K; on behalf of the InC Study Group
Int J Epidemiol. 2013 Dec; 42(6):1649-1659
Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection.
Feld JJ, Grebely J, Matthews GV, Applegate T, Hellard M, Sherker A, Cherepanov V, Petoumenos K, Yeung B, Kaldor JM, Lloyd AR, Dore GJ
PLoS One. 2013 Nov; 8(11):e80003
High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study.
Sacks-Davis R, Aitken CK, Higgs P, Spelman T, Pedrana AE, Bowden S, Bharadwaj M, Nivarthi UK, Suppiah V, George J, Grebely J, Drummer HE, Hellard M
PLoS One. 2013 Nov; 8(11):e80216
Hepatitis C transmission and treatment in contact networks of people who inject drugs.
Rolls DA, Sacks-Davis R, Jenkinson R, McBryde E, Pattison P, Robins G, Hellard M
PLoS One. 2013 Nov; 8(11):e78286
Increasing access by priority populations to Australian sexual health clinics.
Ali H, Donovan B, Fairley CK, Chen MY, O'Connor CC, Grulich AE, McNulty A, Ryder N, Hellard ME, Guy RJ; ACCESS Collaboration."
Sex Transm Dis. 2013 Oct; 40(10):819-821
Quantifying current hepatitis C virus incidence in Egypt - Response to letter by Miller and Abu-Raddad.
Breban R, Doss W, Esmat G, Elsayed M, Hellard M, Ayscue P, Albert M, Fontanet A, Mohamed MK
J Viral Hepat. 2013 Sep; 20(9):668
Are Australian sexual health clinics attracting priority populations?
Ali H, Donovan B, Fairley CK, Ryder N, McNulty A, Chen MY, Marshall L, O'Connor CC, Dickson B, Grulich AE, Hellard ME, Kaldor JM, Guy RJ
Sex Health. 2013 Aug; 10:456-459
Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis.
Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME
Clin Infect Dis. 2013 Aug; 57 Suppl 2:S80-S89
Direct acting antiviral therapy versus pegylated interferon and ribavirin treatment for chronic hepatitis C infection: a meta-analytical systematic review.
Doyle JS, Thompson AJ, Aspinall EJ, Hutchinson SJ, Hellard ME
Technical Report for the World Health Organisation, Global Hepatitis Programme. 2013 Jul
A systematic review of the effectiveness of antiviral treatment compared with no treatment for chronic HCV.
Doyle JS, Malandkar S, Aspinall EJ, Hall K, Hutchinson SJ, Hellard ME
Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
A systematic review and meta-analysis of targeted HCV antibody testing interventions.
Aspinall EJ, Doyle JS, Corson S, Hunt D, Hellard ME, Hutchinson SJ
Technical Report for World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
A systematic review of interventions to reduce alcohol consumption among individuals with chronic HCV infection.
Hunt D, Doyle JS, Aspinall EJ, Hutchinson SJ, Hellard ME
Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
Pegylated interferon plus ribavirin versus standard interferon plus ribavirin for chronic hepatitis C infection: a meta-analytical systematic review.
Quinn B, Doyle JS, Howell J, Chow SM, Aspinall EJ, Hutchinson SJ, Hellard ME
Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
Introduction of a sexual health practice nurse is associated with increased STI testing of men who have sex with men in primary care.
Snow AF, Vodstrcil LA, Fairley CK, El-Hayek C, Cummings R, Owen L, Roth N, Hellard ME, Chen MY
BMC Infect Dis. 2013 Jul; 13(1):298
Characteristics of a Sexual Network of Behaviorally Bisexual Men in Vientiane, Lao PDR, 2010.
van Gemert C, Vongsaiya K, Hughes C, Jenkinson R, Bowring AL, Sihavong A, Phimphachanh C, Chanlivong N, Toole M, Hellard M
AIDS Educ Prev. 2013 Jun; 25(3):232-243
Maintenance of Th1 HCV-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment.
Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; ATAHC Study Group.
J Gastroenterol Hepatol. 2013 May; 28(11):1170-1781
Preventing hepatitis C virus transmission among young people in the justice system.
Lenton E, White B, Aitken C, Hellard M, Higgs P
Children Youth Serv Rev. 2013 May; 35(5):834-6
Sexual Health Promotion on Social Networking Sites: A Process Evaluation of the FaceSpace Project.
Nguyen P, Gold J, Pedrana A, Chang S, Howard S, Ilic O, Hellard M, Stoové M
J Adolesc Health. 2013 Apr; 53(1):98-104
Comparing short versions of the AUDIT in a community-based survey of young people.
Bowring AL, Gouillou M, Hellard M, Dietze P
BMC Public Health. 2013 Apr; 13(1):301
Increases in newly acquired HIV infections in Victoria, Australia: epidemiological evidence of successful prevention?
Feigin A, El-Hayek C, Hellard M, Pedrana A, Donnan E, Fairley C, Tee BK, Stoové M
Sex Health. 2013 Apr; 10(2):166-170
Modelling a disease-relevant contact network of people who inject drugs
Rolls DA, Wang P, Jenkinson R, Pattison PE, Robins GL, Sacks-Davis R, Daraganova G, Hellard M, McBryde E
Soc Net. 2013 Apr; 35(4):699-710
Towards realistic estimates of HCV incidence in Egypt
Breban R, Doss W, Esmat G, Elsayed M, Hellard M, Ayscue P, Albert M, Fontanet A, Mohamed MK
J Viral Hepat. 2013 Mar; 20(4):294-296
HCV treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.
Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, Hickman M
Hepatology. 2013 Mar; 58(5):1598-1609
Current and emerging antiviral treatments for hepatitis C infection.
Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME
Br J Clin Pharmacol. 2013 Mar; 75(4):931-43
Queer as F**k: Reaching and Engaging Gay Men in Sexual Health Promotion through Social Networking Sites.
Pedrana A, Hellard M, Gold J, Ata N, Chang S, Howard S, Asselin J, Ilic O, Batrouney C, Stoové M
J Med Internet Res. 2013 Feb; 15(2):e25
The spread of influenza A(H1N1)pdm09 in Victorian school children in 2009: implications for revised pandemic planning
Fielding JE, Bergeri I, Higgins N, Kelly HA, Meagher J, McBryde ES, Moran R, Hellard ME, Lester RA
PLoS ONE. 2013 Feb; 8(2-3):e57265
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.
Grebely J, Feld JJ, Applegate T, Matthews GV, Hellard M, Sherker A, Petoumenos K, Zang G, Shaw I, Yeung B, George J, Teutsch S, Kaldor JM, Cherepanov V, Bruneau J, Shoukry NH, Lloyd AR, Dore GJ
Hepatology. 2013 Jan; 57(6):2124-2134
Increasing chlamydia test of re-infection rates using SMS reminders and incentives.
Downing SG, Cashman C, McNamee H, Penney D, Russell DB, Hellard ME
Sex Transm Infect. 2013 Jan; 89(1):16-19
Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME
J Gastroenterol Hepatol. 2013 Jan; 28(4):707-16
Increased hepatitis C virus vaccine clinical trial literacy following a brief intervention among people who inject drugs.
White B, Madden A, Hellard M, Kerr T, Prins M, Page K, Dore GJ, Maher L
Drug Alcohol Rev. 2013 Jan; 32(4):419-425
Hepatitis B virus exposure and vaccination in a cohort of people who inject drugs: What has been the impact of targeted free vaccination?
Winter RJ, Dietze PM, Gouillou M, Hellard ME, Robinson P, Aitken CK
J Gastroenterol Hepatol. 2013 Jan; 28(2):314-322
Chlamydia testing and retesting patterns at family planning clinics in Australia.
Bowring AL, Goller JL, Gouillou M, Harvey C, Bateson D, McNamee K, Read C, Boyle D, Jordan L, Wardle R, Stephens A, Donovan B, Guy R, Hellard M
Sex Health. 2013 Jan; 10(1):74-81
Is rectal gonorrhoea a lead indicator of HIV transmission among men who have sex with men in Victoria, Australia?
Wilkinson AL, Lim MS, Stoové M, Fairley CK, Chen M, El-Hayek C, Denham I, Hellard M
Sex Health. 2013 Jan; 10(2):188-189

2012 (29)

Chlamydia sentinel surveillance in Aboriginal Community Controlled Health Services finds higher testing and positivity rates among younger people.
Goller JL, Ward J, Saunders M, Couzos S, Kaldor J, Hellard M
Aust N Z J Public Health. 2012 Dec; 36(6):577-581
Measuring the accuracy of self-reported height and weight in a community-based sample of young people.
Bowring AL, Peeters A, Freak-Poli R, Lim MS, Gouillou M, Hellard M
BMC Med Res Methodol. 2012 Nov; 12(1):175
Trends in sexual behavior, testing, and knowledge in young people; 2006-2011.
Lim MS, Bowring AL, Gold J, Aitken CK, Hellard ME
Sex Transm Dis. 2012 Nov; 39(11):831-834
Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs.
Sacks-Davis R, Daraganova G, Aitken C, Higgs P, Tracy L, Bowden S, Jenkinson R, Rolls D, Pattison P, Robins G, Grebely J, Barry A, Hellard M
PLoS One. 2012 Oct; 7(10):e47335
Impaired HCV-specific IFN-gamma responses in individuals with HIV who acquire HCV infection correlate with levels of CD4 cells.
Flynn JK, Dore GJ, Matthews G, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; on behalf of the ATAHC Study Group.
J Infect Dis. 2012 Sep; 206(10):1568-1576
Stop the Drama Downunder: A Social Marketing Campaign Increases HIV/Sexually Transmitted Infection Knowledge and Testing in Australian Gay Men.
Pedrana A, Hellard M, Guy R, El-Hayek C, Gouillou M, Asselin J, Batrouney C, Nguyen P, StoovÃ¨ M
Sex Transm Dis. 2012 Aug; 39(8):651-658
The role of viral and host genetics in natural history and treatment of chronic HCV infection.
Doyle JS, Hellard ME, Thompson AJ
Best Pract Res Clin Gastroenterol. 2012 Aug; 26(4):413-427
Public-Private Partnerships for Health Promotion: The Experiences of the S5 Project.
Gold J, Hellard ME, Lim MS, Dixon H, Wakefield M, Aitken CK.
Amer J Health Educat. 2012 Aug; 43(4):250-53
Correlates of Chlamydia trachomatis infection in a primary care sentinel surveillance network.
Lim MS, Goller JL, Guy R, Gold J, Stoové M, Hocking JS, Fairley CK, Henning D, McNamee K, Owen L, Sheehan P, Hellard ME
Sex Health. 2012 Jul; 9(3):247-253
Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.
Hellard ME, Jenkinson R, Higgs P, Stoové MA, Sacks-Davis R, Gold J, Hickman M, Vickerman P, Martin NK
Med J Aust. 2012 Jun; 196(10):638-641
Identifying newly acquired cases of hepatitis C using surveillance: a literature review.
Sacks-Davis R, Van Gemert C, Bergeri I, Stoové M, Hellard M
Epidemiol Infect. 2012 Jun; 140(11):1925-1934
Understanding trends in genital Chlamydia trachomatis can benefit from enhanced surveillance: findings from Australia.
Ali H, Guy RJ, Fairley CK, Wand H, Chen MY, Dickson B, O'Connor CC, Marshall L, Grulich AE, Kaldor JM, Hellard ME, Donovan B; on behalf of the ACCESS Collaboration.
Sex Transm Infect. 2012 May; 88(7):552-557
Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection.
Grebely J, Hellard M, Applegate T, Petoumenos K, Yeung B, Feld JJ, Rawlinson W, Lloyd AR, George J, Kaldor JM, Dore GJ, Matthews GV
AIDS. 2012 May; 26(13):1653-1661
The impact of khat use on East African communities in Melbourne: A preliminary investigation.
Feigin A, Higgs P, Hellard M, Dietze P
Drug Alcohol Rev. 2012 May; 31(3):288-293
Behavioural interventions for preventing hepatitis C infection in people who inject drugs: A global systematic review.
Sacks-Davis R, Horyniak D, Grebely J, Hellard M
Int J Drug Policy. 2012 May; 23(3):176-184
The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design.
Vickerman P, Grebely J, Dore GJ, Sacks-Davis R., Page K, Thomas DL, Osburn WO, Cox AL, Aitken CK, Hickman M, Hellard M
J Infect Dis. 2012 May; 205(9):1342-1350
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine.
Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, Page K, Lloyd AR, Dore GJ; on behalf of the International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC(3))
Lancet Infect Dis. 2012 May; 12(5):408-414
Prevalence survey of dermatological conditions in mountainous north India.
Grills N, Grills C, Spelman T, Stoové M, Hellard M, El-Hayek C, Singh R
Int J Dermatol. 2012 May; 51(5):579-587
Impact of pegylated interferon alfa-2a treatment on mental health during recent hepatitis C virus infection.
Alavi M, Grebely J, Matthews GV, Petoumenos K, Yeung B, Day C, Lloyd AR, Van Beek I, Kaldor JM, Hellard M, Dore GJ, Haber PS; on behalf of the ATAHC Study Group
J Gastroenterol Hepatol. 2012 May; 27(5):957-965
Non-cirrhotic portal hypertension in HIV mono-infected patients.
Jackson BD, Doyle JS, Hoy JF, Roberts SK, Colman J, Hellard ME, Sasadeusz JJ, Iser DM
J Gastroenterol Hepatol. 2012 Apr; 27(9):1512-1519
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.
Grebely J, Pham ST, Matthews GV, Petoumenos K, Bull RA, Yeung B, Rawlinson W, Kaldor J, Lloyd A, Hellard M, Dore GJ, White PA; On behalf of the ATAHC Study Group.
Hepatology. 2012 Apr; 55(4):1058-1069
Modelling hepatitis C transmission over a social network of injecting drug users.
Rolls DA, Daraganova G, Sacks-Davis R, Hellard M, Jenkinson R, McBryde E, Pattison PE, Robins GL
J Theor Biol. 2012 Mar; 297:73-87
Missed opportunities--low levels of chlamydia retesting at Australian general practices, 2008-2009.
Bowring AL, Gouillou M, Guy R, Kong FY, Hocking J, Pirotta M, Heal C, Brett T, Donovan B, Hellard M; on behalf of the ACCESS Collaboration.
Sex Transm Infect. 2012 Mar; 88(5):330-334
Know your limits: Awareness of the 2009 Australian alcohol guidelines among young people.
Bowring AL, Gold J, Dietze P, Gouillou M, Van Gemert C, Hellard ME
Drug Alcohol Rev. 2012 Mar; 31(2):213-223
Developing health promotion interventions on social networking sites: recommendations from The FaceSpace Project.
Gold J, Pedrana AE, Stoové MA, Chang S, Howard S, Asselin J, Ilic O, Batrouney C, Hellard ME
J Med Internet Res. 2012 Feb; 14(1):e30
Incidence and risk factors associated with chlamydia in men who have sex with men: a cohort analysis of Victorian Primary Care Network for Sentinel Surveillance data.
Wilkinson A, El-Hayek C, Fairley CK, Leslie D, Roth N, Tee BK, Hellard ME, Stoové M
Sex Transm Infect. 2012 Feb; 88(5):319-324
High rates of undiagnosed HIV infections in a community sample of gay men in Melbourne, Australia.
Pedrana AE, Hellard ME, Wilson K, Guy R, StoovÃ© M
JAIDS. 2012 Jan; 59(1):94-99
Impact of text and email messaging on the sexual health of young people: a randomised controlled trial.
Lim MS, Hocking JS, Aitken CK, Fairley CK, Jordan L, Lewis JA, Hellard ME
J Epidemiol Community Health. 2012 Jan; 66(1):69-74
The difference in self-reported and biological measured HIV prevalence: Implications for HIV prevention.
Pedrana AE, Hellard ME, Guy R, Wilson K, Stoové M
AIDS Behav. 2012 Jan; 16(6):1454-1463

2011 (22)

Exploring the sexual networks of men who have sex with men and women in Hanoi, Vietnam - Summary Report
Siobhan Reddel, Pham Hanh Van, Nguyen Van Thuy, Peter Higgs, Khoat Van Dang, Rebecca Jenkinson, Caroline Van Gemert, Chad Hughes, Margaret Hellard, Mike Toole AM
Exploring the sexual networks of men who have sex with men and women in Hanoi, Vietnam - Final Report
Siobhan Reddel, Pham Hanh Van, Nguyen Van Thuy, Peter Higgs, Khoat Van Dang, Rebecca Jenkinson, Caroline Van Gemert, Chad Hughes, Margaret Hellard, Mike Toole
Heroin and other opioids
Dietze P, Degenhardt L, Kinner S, Hellard M, King T
Prevention Research Quarterly. 2011 Sep; 16:1-12
Sexual history taking and sexually transmissible infection screening practices among men who have sex with men: a survey of Victorian general practitioners.
Barber B, Hellard M, Jenkinson R, Spelman T, Stoové M
Sex Health. 2011 Sep; 8(3):349-354
Risk factors for HIV seroconversion in men who have sex with men in Victoria, Australia: results from a sentinel surveillance system.
Guy RJ, Spelman T, Stoové M, El-Hayek C, Goller J, Fairley CK, Leslie D, Tee B, Roth N, Grulich AE, Hellard ME
Sex Health. 2011 Sep; 8(3):319-329
Intrahousehold transmission of pandemic (H1N1) 2009 virus, Victoria, Australia.
van Gemert C, Hellard M, McBryde ES, Fielding J, Spelman T, Higgins N, Lester R, Vally H, Bergeri I
Emerg Infect Dis. 2011 Sep; 17(9):1599-1607
The relationship between personality disorders and mental health, substance use severity and quality of life among injecting drug users.
Gibbie TM, Hides LM, Cotton SM, Lubman DI, Aitken C, Hellard M
Med J Aust. 2011 Aug; 195(3):S16-S21
Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users.
Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA
J Viral Hepat. 2011 Aug; 18(8):549-561
A systematic examination of the use of Online social networking sites for sexual health promotion.
Gold J, Pedrana AE, Sacks-Davis R, Hellard ME, Chang S, Howard S, Keogh L, Hocking JS, Stoové MA
BMC Public Health. 2011 Jul; 11:583
Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.
Grebely J, Matthews GV, Hellard M, Shaw D, van Beek I, Petoumenos K, Alavi M, Yeung, B, Haber PS, Lloyd, AR, Kaldor JM, Dore GJ
J Hepatol. 2011 Jul; 55(1):76-85
Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence.
Higgs P, Sacks-Davis R, Gold J, Hellard M
Hepat Mon. 2011 Jul; 11(7):513-518
The Australian national binge drinking campaign: campaign recognition among young people at a music festival who report risky drinking.
van Gemert C, Dietze P, Gold J, Sacks-Davis R, StoovÃ© M, Vally H, Hellard M
BMC Public Health. 2011 Jun; 11:482
Impact evaluation of a youth sexually transmissible infection awareness campaign using routinely collected data sources.
Gold J, Goller J, Hellard M, Lim MS, Hocking J, Fairley CK, Spelman T, McNamee K, Clift P, Guy R
Sex Health. 2011 Jun; 8(2):234-241
Re-testing for chlamydia at sexual health services in Australia, 2004-08.
Guy R, Wand H, Franklin N, Fairley CK, Chen MY, O'Connor CC, Marshall L, Grulich AE, Kaldor JM, Hellard M, Donovan B On Behalf Of The Access Collaboration
Sex Health. 2011 Jun; 8(2):242-247
Exploring the sexual networks of men who have sex with men and women in Lao PDR - Summary Report
Chad Hughes, Caroline van Gemert, Kongchay Vongsaiya, Rebecca Jenkinson, Amphoy Sihavong, Chansy Phimphachanh, Niramonh Chanlivong, Margaret Hellard, Mike Toole
Exploring the sexual networks of men who have sex with men and women in Lao PDR - Final Report
Chad Hughes, Caroline van Gemert, Kongchay Vongsaiya, Rebecca Jenkinson, Amphoy Sihavong, Chansy Phimphachanh, Niramonh Chanlivong, Margaret Hellard, Mike Toole
Determining the impact of text messaging for sexual health promotion to young people.
Gold J, Lim MS, Hocking JS, Keogh LA, Spelman T, Hellard ME
Sex Transm Dis. 2011 Apr; 38(4):247-252
A randomised controlled trial using mobile advertising to promote safer sex and sun safety to young people.
Gold J, Aitken CK, Dixon HG, Lim MS, Gouillou M, Spelman T, Wakefield M, Hellard ME
Health Educ Res. 2011 Mar
Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C.
Matthews GV, Pham ST, Hellard M, Grebely J, Zhang L, Oon A, Marks P, van Beek I, Rawlinson W, Kaldor JM, Lloyd A, Dore GJ, White PA; on behalf of the ATAHC Study Group
Clin Infect Dis. 2011 Mar; 52(6):803-811
Australian general practitioner chlamydia testing rates among young people.
Kong FY, Guy RJ, Hocking JS, Merritt T, Pirotta M, Heal C, Bergeri I, Donovan B, Hellard ME
Med J Aust. 2011 Mar; 194(5):249-252
What's your "porn star" name? A novel method of identifying research participants.
Lim MS, Bowring A, Gold J, Hellard ME
Sex Transm Dis. 2011 Feb; 38(2):150-151
Antigen-driven patterns of TCR bias are shared across diverse outcomes of human hepatitis C virus infection.
Miles JJ, Thammanichanond D, Moneer S, Nivarthi UK, Kjer-Nielsen L, Tracy SL, Aitken CK, Brennan RM, Zeng W, Marquart L, Jackson D, Burrows SR, Bowden DS, Torresi J, Hellard M, Rossjohn J, McCluskey J, Bharadwaj M
J Immunol. 2011 Jan; 186(2):901-912

2010 (18)

What's in a message? Delivering sexual health promotion to young people in Australia via text messaging.
Gold J, Lim MS, Hellard ME, Hocking JS, Keogh LA
BMC Public Health. 2010 Dec; 10:792
The changing age distribution of men who have sex with men diagnosed with HIV in Victoria.
El-Hayek C, Bergeri I, Hellard ME, Pedrana AE, Higgins N, Breschkin A, Stoové M
Med J Aust. 2010 Dec; 193(11-12):655-658
Establishing a linked sentinel surveillance system for blood-borne viruses and sexually transmissible infections: methods, system attributes and early findings.
Goller JL, Guy RJ, Gold J, Lim MS, El-Hayek C, Stoové MA, Bergeri I, Fairley CK, Leslie DE, Clift P, White B, Hellard ME
Sex Health. 2010 Dec; 7(4):425-433
Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities.
Maher L, White B, Hellard M, Madden A, Prins M, Kerr T, Page K
Vaccine. 2010 Oct; 28(45):7273-7278
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.
Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, Yeung B, Marks P, Rawlinson W, Lloyd AR, Booth D, Kaldor JM, George J, Dore GJ; for the ATAHC Study Group.
Hepatology. 2010 Oct; 52(4):1216-1224
Randomised controlled trial of paper, online and SMS diaries for collecting sexual behaviour information from young people.
Lim MS, Sacks-Davis R, Aitken CK, Hocking JS, Hellard ME
J Epidemiol Community Health. 2010 Oct; 64(10):885-889
Does the frequency of HIV and STI testing among men who have sex with men in primary care adhere with Australian guidelines?
Guy R, Goller JL, Spelman T, El-Hayek C, Gold J, Lim M, Leslie D, Tee BK, Roth N, Anderson J, Fairley CK, Kaldor J, Hellard M
Sex Transm Infect. 2010 Oct; 86(5):371-376
A new national Chlamydia Sentinel Surveillance System in Australia: evaluation of the first stage of implementation.
Guy RJ, Kong F, Goller J, Franklin N, Bergeri I, Dimech W, Reilly N, Sullivan E, Ward J, Kaldor JM, Hellard M, Donovan B; ACCESS Collaboration
Commun Dis Intell. 2010 Sep; 34(3):319-328
Home-based chlamydia testing of young people attending a music festival--who will pee and post?
Sacks-Davis R, Gold J, Aitken CK, Hellard ME
BMC Public Health. 2010 Jun; 10:376
Further research required to determine link between khat consumption and driver impairment.
Feigin A, Higgs P, Hellard M, Dietze P
Bull World Health Organ. 2010 Jun; 88(6):480
Sex and sport: sexual risk behaviour in young people in rural and regional Victoria.
Kong FY, Hocking JS, Link CK, Chen MY, Hellard ME
Sex Health. 2010 Jun; 7(2):205-211
African Australians living with HIV: a case series from Victoria.
Lemoh CN, Baho S, Grierson J, Hellard M, Street A, Biggs BA
Sex Health. 2010 Jun; 7(2):142-148
The utility of voluntary counselling and testing data as a source of information on HIV prevalence: a systematic review.
Horyniak D, Guy R, Prybylski D, Hellard M, Kaldor J
Int J STD AIDS. 2010 May; 21(5):305-311
Antibody persistence six years after two doses of combined hepatitis A and B vaccine.
Burgess MA, McIntyre PB, Hellard M, Ruff TA, Lefevre I, Bock HL
Vaccine. 2010 Mar; 28(10):2222-2226
Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study.
Grebely J, Petoumenos K, Matthews GV, Haber P, Marks P, Lloyd AR, Kaldor JM, Dore GJ, Hellard M; for the ATAHC Study Group
Drug Alcohol Depend. 2010 Mar; 107(2-3):244-249
Surveillance of drug use among young people attending a music festival in Australia, 2005-2008.
Lim MS, Sacks-Davis R, Aitken CK, Hocking JS, Hellard ME
Drug Alcohol Rev. 2010 Mar; 29(2):150-156
Incentive payments to general practitioners aimed at increasing opportunistic testing of young women for chlamydia: a pilot cluster randomised controlled trial.
Bilardi JE, Fairley CK, Temple-Smith MJ, Pirotta MV, Mc Namee KM, Bourke S, Gurrin LC, Hellard M, Sanci LA, Wills MJ, Walker J, Chen MY, Hocking JS
BMC Public Health. 2010 Feb; 10:70
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.
Dore GJ, Hellard M, Matthews G, Grebely J, Haber PS, Petoumenos K, Yeung B, Marks P, van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, Kaldor JM; Australian Trial In Acute Hepatitis C Study Group
Gastroenterology. 2010 Jan; 138(1):123-35

2009 (23)

Sporadic gastroenteritis and recreational swimming in a longitudinal community cohort study in Melbourne, Australia.
Dale K, Wolfe R, Sinclair M, Hellard M, Leder K
Am J Epidemiol. 2009 Dec; 170(12):1469-1477
Factors influencing a self-limiting HIV outbreak among ethnic Vietnamese injecting drug users in Melbourne, Australia.
Higgs P, Yohannes K, Hellard M, Maher L
Qual Health Res. 2009 Dec; 19(12):1690-1701
Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection.
Li S, Floess S, Hamann A, Gaudieri S, Lucas A, Hellard M, Roberts S, Paukovic G, Plebanski M, Loveland BE, Aitken C, Barry S, Schofield L, Gowans EJ
PLoS Pathog. 2009 Dec; 5(12):e1000707
The role of general practitioners in managing and treating hepatitis C.
Hellard ME, Wang YH
Med J Aust. 2009 Nov; 191(10):523-524
Surveillance of STI risk behaviour among young people attending a music festival in Australia, 2005-08.
Lim MS, Hellard ME, Aitken CK, Hocking JS
Aust N Z J Public Health. 2009 Oct; 33(5):482-484
The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006.
Gidding HF, Topp L, Middleton M, Robinson K, Hellard M, McCaughan G, Maher L, Kaldor JM, Dore GJ, Law MG
J Gastroenterol Hepatol. 2009 Oct; 24(10):1648-1654
The "work" of women when considering and using interventions to reduce mother-to-child transmission (MTCT) of HIV.
Giles ML, Hellard ME, Lewin SR, O'Brien ML
AIDS Care. 2009 Oct; 21(10):1230-1237
The Victorian hepatitis C education program for GPs--an evaluation.
Wang YH, Guy R, Hellard M
Aust Fam Physician. 2009 Sep; 38(9):749-752
Limits to relying on expert information: the Delphi technique in a study of ethnic Vietnamese injection drug users in Melbourne, Australia.
Nguyen OK, Higgs PG, Hellard ME
Soc Work Public Health. 2009 Sep; 24(5):371-379
Hepatitis C treatment for injection drug users: a review of the available evidence.
Hellard M, Sacks-Davis R, Gold J.
Clin Infect Dis. 2009 Aug; 49(4):561-573
TCD8 response in diverse outcomes of recurrent exposure to hepatitis C virus.
Bharadwaj M, Thammanichanond D, Aitken CK, Moneer S, Drummer HE, Tracy S, Holdsworth R, Bowden S, Jackson D, Hellard M, Torresi J, McCluskey J
Immunol Cell Biol. 2009 Aug; 87(6):464-472
Heroin-gel capsule cocktails and groin injecting practices among ethnic Vietnamese in Melbourne, Australia.
Higgs P, Dwyer R, Duong D, Thach ML, Hellard M, Power R, Maher L
Int J Drug Policy. 2009 Jul; 20(4):340-346
Discrepancies between young people's self-reported sexual experience and their perceptions of 'normality'.
Lim MS, Aitken CK, Hocking JS, Hellard ME
Sex Health. 2009 Jun; 6(2):171-172
Delayed diagnosis of HIV infection in Victoria 1994 to 2006.
Lemoh C, Guy R, Yohannes K, Lewis J, Street A, Biggs B, Hellard M
Sex Health. 2009 Jun; 6(2):117-122
The impact of immigration on the burden of HIV infection in Victoria, Australia.
Horyniak D, StoovÃ© M, Yohannes K, Breschkin A, Carter T, Hatch B, Tomnay J, Hellard M, Guy R
Sex Health. 2009 Jun; 6(2):123-128
Can data from HIV voluntary counselling and testing be used to assess the impact of public health interventions? A literature review.
Guy RJ, Prybylski D, Fairley CK, Hellard ME, Kaldor J
Int J STD AIDS. 2009 Jun; 20(6):378-383
Variable uptake of recommended interventions to reduce mother-to-child transmission of HIV in Australia, 1982-2005 (REPLY)
Giles ML, McDonald AM, Elliott EJ, Ziegler JB, Hellard ME, Lewin SR, Kaldor JM
Med J Aust. 2009 Jun; 190:220-221
Sex and sport: chlamydia screening in rural sporting clubs.
Kong FY, Hocking JS, Link CK, Chen MY, Hellard ME
BMC Infect Dis. 2009 May; 9:73
Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
Miller ER, Hellard ME, Bowden S, Bharadwaj M, Aitken CK
J Infect. 2009 May; 58(5):375-382
Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C.
Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, McCaughan G, Sasadeusz J, White P, Rawlinson W, Lloyd A, Kaldor J, Dore GJ
Clin Infect Dis. 2009 Mar; 48(5):650-658
Antenatal screening practice for infectious diseases by general practitioners in Australia.
Giles ML, Pedrana A, Jones C, Garland S, Hellard M, Lewin SR
Aust N Z J Obstet Gynaecol. 2009 Feb; 49(1):39-44
Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users.
Dwyer R, Topp L, Maher L, Power R, Hellard M, Walsh N, Jauncey M, Conroy A, Lewis J, Aitken C
Drug Alcohol Depend. 2009 Feb; 100(1-2):9-16
Does Information about IDUs' Injecting Networks Predict Exposure to the Hepatitis C Virus?
Aitken CK, Lewis JA, Hocking JS, Bowden DS, Hellard ME
Hepatitis Monthly. 2009 Jan; 9(1):17-23

2008 (19)

Using a surveillance system to identify and treat newly acquired hepatitis C infection.
Walsh N, Lim M, Hellard M
J Gastroenterol Hepatol. 2008 Dec; 23(12):1891-1894
High incidence of hepatitis C virus reinfection in a cohort of injecting drug users.
Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, Drummer H, Hetlard M
Hepatology. 2008 Dec; 48(6):1746-1752
Working with West African migrant communities on HIV prevention in Australia.
Lemoh C, Biggs BA, Hellard M
Sex Health. 2008 Dec; 5(4):313-314
Gender, culture and harm: an exploratory study of female heroin users of Vietnamese ethnicity.
Higgs P, Owada K, Hellard M, Power R, Maher L
Cult Health Sex. 2008 Oct; 10(7):681-696
Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response.
Thammanichanond D, Moneer S, Yotnda P, Aitken C, Earnest-Silveira L, Jackson D, Hellard M, McCluskey J, Torresi J, Bharadwaj M
Clin Immunol. 2008 Sep; 128(3):329-339
Registered post achieved a higher response rate than normal mail--a randomized controlled trial.
Pedrana A, Hellard M, Giles M
J Clin Epidemiol. 2008 Sep; 61(9):896-899
Variable uptake of recommended interventions to reduce mother-to-child transmission of HIV in Australia, 1982-2005.
Giles ML, McDonald AM, Elliott EJ, Ziegler JB, Hellard ME, Lewin SR, Kaldor JM
Med J Aust. 2008 Aug; 189(3):151-154
Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region.
Wright E, Brew B, Arayawichanont A, Robertson K, Samintharapanya K, Kongsaengdao S, Lim M, Vonthanak S, Lal L, Sarim C, Huffam S, Li P, Imran D, Lewis J, Lun WH, Kamarulzaman A, Tau G, Ali ST, Kishore K, Bain MP, Dwyer R, McCormack G, Hellard M, Cherry C, McArthur J, Wesselingh S
Neurology. 2008 Jul; 71(1):50-56
A cross-sectional survey of young people attending a music festival: associations between drug use and musical preference.
Lim MS, Hellard ME, Hocking JS, Aitken CK
Drug Alcohol Rev. 2008 Jul; 27(4):439-441
Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza.
Goy K, Von Bibra S, Lewis J, Laurie K, Barr I, Anderson D, Hellard M, Ffrench R
Influenza Other Respi Viruses. 2008 Jul; 2(4):115-125
Characteristics of HIV diagnoses in Australia, 1993-2006.
Guy RJ, McDonald AM, Bartlett MJ, Murray JC, Giele CM, Davey TM, Appuhamy RD, Knibbs P, Coleman D, Hellard ME, Grulich AE, Kaldor JM
Sex Health. 2008 Jun; 5(2):91-96
Enhanced case detection for newly acquired hepatitis C infection: epidemiological findings and health service implications.
Guy R, Devadason D, Lim M, Higgins N, Pedrana A, Gibson K, Lewis J, Spelman T, White B, Kaldor J, Hellard M
Commun Dis Intell. 2008 Jun; 32(2):250-256
Risk behaviours and blood borne virus exposure for transient workers in rural Victoria.
Pedrana A, Aitken C, Higgs P, Hellard M
Aust J Rural Health. 2008 Jun; 16(3):143-149
SMS STI: a review of the uses of mobile phone text messaging in sexual health.
Lim MS, Hocking JS, Hellard ME, Aitken CK
Int J STD AIDS. 2008 May; 19(5):287-290
Consecutive infections and clearances of different hepatitis C virus genotypes in an injecting drug user.
Aitken CK, Tracy SL, Revill P, Bharadwaj M, Bowden DS, Winter RJ, Hellard ME
J Clin Virol. 2008 Apr; 41(4):293-296
Buprenorphine injection in Melbourne, Australia - an update.
Aitken CK, Higgs PG, Hellard ME
Drug Alcohol Rev. 2008 Mar; 27(2):197-199
Barriers to the delivery of the hepatitis B birth dose: a study of five Papua New Guinean hospitals in 2007.
Downing SG, Lagani W, Guy R, Hellard M
P N G Med J. 2008 Mar; 51(1-2):47-55
Integrating enhanced hepatitis C testing and counselling in research.
Winter R, Nguyen O, Higgs P, Armstrong S, Duong D, Thach ML, Aitken C, Hellard M
Int J Drug Policy. 2008 Feb; 19(1):66-70
The rise of infectious syphilis in Victoria and the impact of enhanced clinical testing.
Allen K, Guy R, Leslie D, Goller J, Medland N, Roth N, Lewis J, Hellard M
Aust N Z J Public Health. 2008 Feb; 32(1):38-42

2007 (14)

Modelling the hepatitis C virus epidemic in Australia.
Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, George J, Kaldor J, Karvelas M, Li J, Maher L, McGregor S, Hellard M, Poeder F, Quaine J, Stewart K, Tyrrell H, Weltman M, Westcott O, Wodak A, Law M
Drug Alcohol Depend. 2007 Dec; 91(2-3):228-235
HIV diagnoses in Australia: diverging epidemics within a low-prevalence country.
Guy RJ, McDonald AM, Bartlett MJ, Murray JC, Giele CM, Davey TM, Appuhamy RD, Knibbs P, Coleman D, Hellard ME, Grulich AE, Kaldor JM
Med J Aust. 2007 Oct; 187(8):437-440
Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.
Nguyen OK, Dore GJ, Kaldor JM, Hellard ME; on behalf of the ATAHC Protocol Steering Committee
Int J Drug Policy. 2007 Oct; 18(5):447-451
Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al.
Matthews GV, Hellard M, Kaldor J, Lloyd A, Dore GJ
AIDS. 2007 Oct; 21(15):2112-2113
Cambodian-born individuals diagnosed with HIV in Victoria: epidemiological findings and health service implications.
Ayton DR, Guy RJ, Woolley IJ, Hellard ME
Sex Health. 2007 Sep; 4(3):209
A new surveillance system for monitoring HIV infection in Victoria, Australia.
Guy R, Lim MSC, Wang YH, Medland N, Anderson J, Rothe N, Hellard ME
Sex Health. 2007 Sep; 4(3):195-199
Tattooing in prisons--not such a pretty picture.
Hellard ME, Aitken CK, Hocking JS
Am J Infect Control. 2007 Sep; 35(7):477-480
What are the barriers to offering HIV testing in an antenatal setting? A national study of obstetricians.
Giles ML, Garland SM, Lewin SR, Hellard ME
AIDS. 2007 Jul; 21(12):1601-1606
The feasibility of recruiting young men in rural areas from community football clubs for STI screening.
Gold, J, Hocking, J, Hellard, M
Aust N Z J Public Health. 2007 Jun; 31(3):243-246
Chlamydia trachomatis prevalence in heterosexual men in Melbourne: a community-based study.
Wade AJ, Hocking LS, Hellard ME
Sex Health. 2007 Jun; 4(2):137-138
Sexual-risk behaviour, self-perceived risk and knowledge of sexually transmissible infections among young Australians attending a music festival.
Lim MS, Hellard ME, Aitken CK, Hocking JS
Sex Health. 2007 Mar; 4(1):51-56
Risk factors for incident HIV infection in men having sex with men: a case-control study.
Read TRH, Hocking J, Sinnott V, Hellard M
Sex Health. 2007 Mar; 4(1):35-39
Reliability and validity of the Kessler 10 and Patient Health Questionnaire among injecting drug users.
Hides L, Lubman DI, Devlin H, Cotton S, Aitken C, Gibbie T, Hellard M
Aust N Z J Psychiatry. 2007 Feb; 41(2):166-168
Blood-borne viruses and risk behaviours among injecting drug users recruited from needle and syringe programs in Victoria's eastern metropolitan region
Lim MS, Sundaram K, Aitken CK, Hellard ME
Aust J Prim Health. 2007 Jan; 13(3):69-76

2006 (8)

The prevalence and risk behaviours associated with the transmission of blood-borne viruses among ethnic-Vietnamese injecting drug users.
Hellard ME, Nguyen OK, Guy RJ, Jardine D, Mijch A, Higgs PG
Aust N Z J Public Health. 2006 Dec; 30(6):519-525
Chlamydia testing in general practice - a survey of Victorian general practitioners.
Hocking JS, Lim MS, Vidanapathirana J, Read TR, Hellard M
Sex Health. 2006 Dec; 3(4):241-244
A chlamydia prevalence survey of young women living in Melbourne, Victoria.
Hocking JS, Willis J, Tabrizi S, Fairley CK, Garland SM, Hellard M
Sex Health. 2006 Dec; 3(4):235-240
Acute Hepatitis C treatment Uptake in the Victorian Population.
Walsh N, Lim M, Nguyen O, Von Bibra S, Dore G, and Hellard M
18th Annual Conference. 2006 Oct; Abstract page 153
The evidence for a change in antenatal HIV screening policy in Australia.
Giles ML, Hellard ME, Lewin SR, Mijch AM
Med J Aust. 2006 Aug; 185(4):217-220
Postal surveys of physicians gave superior response rates over telephone interviews in a randomized trial.
Hocking JS, Lim MS, Read T, Hellard M
J Clin Epidemiol. 2006 May; 59(5):521-524
Impact of an education campaign on management in pregnancy of women infected with a blood-borne virus.
Giles ML, Garland SM, Grover SR, Lewin SR, Hellard ME
Med J Aust. 2006 Apr; 184(8):389-392
A profile of HIV testing in Victoria, 1984 to 2004.
Lim M, Guy R, Hellard M
Commun Dis Intell. 2006 Jan; 30(3):366-372

2005 (5)

The case of the disappearing teaspoons: longitudinal cohort study of the displacement of teaspoons in an Australian research institute.
Lim MSC, Hellard ME, Aitken CK
BMJ. 2005 Dec; 331(7531):1498-1500
Blood-borne viral and sexually transmissible infections among psychiatric populations: what are we doing about them?
Hercus M, Lubman DI, Hellard M
Aust N Z J Psychiatry. 2005 Oct; 39(10):849-855
Sustained increase in infectious syphilis notifications in Victoria.
Guy RJ, Leslie DE, Simpson K, Hatch B, Leydon J, Hellard ME, Kelly HA
Med J Aust. 2005 Aug; 183(4):218
Improving HIV surveillance in Victoria: the role of the "detuned" enzyme immunoassay.
Guy RJ, Breschkin AM, Keenan CM, Catton MG, Enriquez AM, Hellard ME
J Acquir Immune Defic Syndr. 2005 Apr; 38(4):495-499
A study to investigate the impact of the initiation of highly active antiretroviral therapy on the hepatitis C virus viral load in HIV/HCV-coinfected patients.
Mijch A, Sasadeusz J, Hellard M, Dunne M, McCaw R, Bowden S, Gowans EJ
Antivir Ther. 2005 Jan; 10(2):277-284

2004 (9)

Change in hepatitis C virus genotype in injecting drug users.
Aitken C, McCaw R, Jardine D, Bowden S, Higgs P, Nguyen O, Crofts N, Hellard M
J Med Virol. 2004 Dec; 74(4):543-545
The molecular epidemiology of HIV type 1 among Vietnamese Australian injecting drug users in Melbourne, Australia.
Ryan CE, Elliott JH, Middleton T, Mijch AM, Street AC, Hellard M, Crofts N, Crowe SM, Oelrichs RB
AIDS Res Hum Retroviruses. 2004 Dec; 20(12):1364-1367
Rising HIV infection in Victoria: an analysis of surveillance data.
Hocking J, Keenan C, Catton M, Breschkin A, Guy R, Hellard M
Aust N Z J Public Health. 2004 Jun; 28(3):217-219
The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities.
Hellard ME, Hocking JS, Crofts N
Epidemiol Infect. 2004 Jun; 132(3):409-415
HIV and pregnancy in Australia.
Giles ML, Mijch AM, Garland SM, Grover SR, Hellard ME
Aust N Z J Obstet Gynaecol. 2004 Jun; 44(3):197-204
An audit of obstetricians' management of women potentially infected with blood-borne viruses.
Giles ML, Sasadeusz JJ, Garland SM, Grover SR, Hellard ME
Med J Aust. 2004 Apr; 180(7):328-332
Indications of immune protection from hepatitis C infection.
Aitken CK, Bowden S, Hellard M, Crofts N
J Urban Health. 2004 Mar; 81(1):58-60
Rising HIV infections in Victoria, the need for a new approach to preventative interventions.
Guy R, Hellard M
Sex Health. 2004 Feb; 1(2):69-71
HIV in prison: what are the risks and what can be done?
Hellard ME, Aitken CK
Sex Health. 2004 Jan; 1(2):107-113

2003 (3)

Risk factors leading to Cryptosporidium infection in men who have sex with men.
Hellard M, Hocking J, Willis J, Dore G, Fairley C
Sex Transm Infect. 2003 Oct; 79(5):412-414
Hepatitis C and pregnancy: an update.
Giles M, Hellard M, Sasadeusz J
Aust N Z J Obstet Gynaecol. 2003 Aug; 43(4):290-293
Investigation of infection control practices and knowledge of hepatitis C among body-piercing practitioners.
Hellard M, Aitken C, Mackintosh A, Ridge A, Bowden S
Am J Infect Control. 2003 Jun; 31(4):215-220

2002 (1)

The rate of gastroenteritis in a large city before and after chlorination.
Hellard ME, Sinclair MI, Dharmage SC, Bailey MJ, Fairley CK
Int J Environ Health Res. 2002 Dec; 12(4):355-360

2001 (2)

A randomized, blinded, controlled trial investigating the gastrointestinal health effects of drinking water quality.
M E Hellard, M I Sinclair, A B Forbes, C K Fairley
Environ Health Perspect. 2001 Aug; 109(8):773-778
Methods used to maintain a high level of participant involvement in a clinical trial.
M E Hellard, M I Sinclair, A B Forbes, C K Fairley
J Epidemiol Community Health. 2001 May; 55(5):348-351

2000 (2)

HIV associated cytomegalovirus retinitis in Melbourne, Australia.
C L Cherry, A M Mijch, J F Hoy, A J Hall, M E Hellard, M Bryant, B DeGraaff, C K Fairley
Sex Transm Infect. 2000 Jun; 76(3):221
Prevalence of enteric pathogens among community based asymptomatic individuals.
M E Hellard, M I Sinclair, G G Hogg, C K Fairley
J Gastroenterol Hepatol. 2000 Mar; 15(3):290-293

1998 (3)

Protozoa in drinking water: is legislation the best answer?
M I Sinclair, C K Fairley, M E Hellard
Med J Aust. 1998 Sep; 169(6):296-297
Detection of an aberrant motile larval form in the brain of a patient with neurocysticercosis.
M E Hellard, A C Street, P D Johnson, E A Popovic, G V Brown
Clin Infect Dis. 1998 Aug; 27(2):391-393
Tuberculous pancreatic abscess in an HIV antibody-negative patient: case report and review.
A W Jenney, R W Pickles, M E Hellard, D W Spelman, A J Fuller, W J Spicer
Scand J Infect Dis. 1998 Jan; 30(2):99-104

1997 (6)

Safe drinking water.
A A Padiglione, M E Hellard, M I Sinclair, C K Fairley
Med J Aust. 1997 Jun; 166(12):670
Drinking water and microbiological pathogens--issues and challenges for the year 2000.
M E Hellard, M I Sinclair, C L Streeton, C K Fairley
J Public Health Med. 1997 Jun; 19(2):129-131
Pancreatic tuberculosis (TB) in HIV infection.
A Jenney, R Pickles, M Hellard, D Spelman, A Fuller, W J Spicer
Aust N Z J Med. 1997 Jun; 27(3):349-350
Cryptosporidiosis in patients with AIDS.
R L Stuart, M E Hellard, D Jolley, D Spelman, J Hoy, E M Stevenson, M T Yates, N J Ryan, C K Fairley
Int J STD AIDS. 1997 May; 8(5):339-341
Gastroenteritis in Australia: who, what, where, and how much?
M Hellard, C K Fairley
Aust N Z J Med. 1997 Apr; 27(2):147-149
Totally implantable venous access device infections in patients with AIDS.
M Hellard, A Fuller, D Spelman, W J Spicer, R Pickles, A Jenney
AIDS. 1997 Apr; 11(5):697-698

News Articles (143)

2023 (1)

Modelling indicates Omicron variants going undiagnosed

2022 (2)

2021 (31)

2020 (18)

2019 (14)

2018 (14)

2017 (14)

2016 (15)

2015 (9)

2014 (14)

2013 (5)

2012 (4)

2011 (2)

Contact Details

Telephone

+61385062304

Email

margaret.hellard@burnet.edu.au

Twitter

@MargaretHellard

Working Groups

Programs

Discipline

Public Health

Support Us

About

People

Research

COVID-19

Changing Lives

Opportunities